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Abstract 
Ionized calcium (Ca2+), acting as an intracellular messenger, controls numerous 
biological processes that are essential for life. However, it is also able to convey signals that 
result in cell death. The fidelity of Ca2+ as a universal second messenger therefore depends on 
mechanisms that specifically and dynamically regulate its levels within a cell, as well as 
maintain resting intracellular Ca2+ concentration ([Ca2+]i) very low. One such mechanism for 
Ca2+ signaling and homeostasis is the plasma membrane Ca2+-ATPase (PMCA), which is a 
primary active Ca2+ transporter that translocates Ca2+ from a low intracellular Ca2+ 
environment to a high extracellular environment. There are four mammalian PMCA isoforms 
(PMCA1−4), which are differentially expressed depending on tissue or cell type. PMCA 
isoforms possess different sensitivities to biochemical regulation of Ca2+ efflux activity and 
are also able to subtly alter the dynamics of Ca2+ signals. These properties suggest that the 
PMCA is not merely a trivial mechanism for Ca2+ extrusion but is influential in contributing 
to the Ca2+ signaling requirements and unique physiology of different cells.  
 
The indispensable nature of Ca2+ signaling in organs such as the brain, heart and 
skeletal muscle has been the studied extensively but little is known about the roles and 
regulation of Ca2+ in the mammary gland. This is despite the fact that the mammary gland is a 
site of extensive Ca2+ flux during lactation. However, cumulating evidence indicates that 
upregulation of PMCA2 expression in the mammary gland is a major mechanism for milk 
Ca2+ enrichment. Therefore, the PMCA is likely to be an important mediator of bulk Ca2+ 
homeostasis in the mammary gland. Studies in other model systems also suggest that PMCAs 
may regulate other cellular processes such as cell proliferation, differentiation and apoptosis 
that are required for normal mammary gland physiology. These basic cellular processes are 
also disturbed in breast cancer and hence deregulation of PMCA expression in the mammary 
gland may have pathophysiological consequences. Previous studies show that PMCA1 
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expression is greater in tumorigenic MCF-7 and MDA-MB-231 human breast cancer cells 
compared to non-tumorigenic MCF-10A human breast epithelial cells. Furthermore, the 
expression of PMCA1b and PMCA4b is lower in human skin and lung fibroblasts 
neoplastically transformed by simian virus 40, compared to non-transformed counterparts. It 
is therefore hypothesized that regulation of PMCA isoform expression is disrupted in breast 
cancer and that inhibition of PMCA expression in an in vitro model of breast cancer has 
important effects in modulating intracellular Ca2+ homeostasis, cell proliferation, 
differentiation and apoptosis.  
 
This thesis describes the use of real time RT-PCR to compare PMCA isoform mRNA 
expression in tumorigenic and non-tumorigenic mammary gland epithelial cells. It 
demonstrates that particular breast cancer cell lines overexpress PMCA2, an isoform with 
restricted tissue distribution and which is present in abundant amounts in the lactating rat 
mammary gland. Thus, some breast cancers may be characterized by the overexpression of 
Ca2+ transporters that are normally upregulated during the physiological course of lactation. 
The pathophysiological significance of PMCA2 overexpression in breast cancer is uncertain 
and future investigations should look at whether levels of PMCA isoform expression correlate 
with malignancy, prognosis or survival.  
 
To address the second hypothesis of this thesis, a stable MCF-7 Tet-off human breast 
cancer cell line able to conditionally express PMCA antisense was generated. This strategy 
was necessary due to the current lack of specific pharmacological inhibitors of the PMCA. 
This thesis shows that PMCA antisense expression significantly inhibits PMCA protein 
expression, while subtly affecting PMCA-mediated Ca2+ efflux without causing cell death. 
However, it also reveals that inhibition of PMCA expression has major effects in mediating 
cell proliferation and cell cycle progression. Moderate changes in PMCA expression and 
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PMCA-mediated Ca2+ transport result in dramatic consequences in MCF-7 cell proliferation. 
These studies not only support the supposition that modulation of Ca2+ signaling is a viable 
therapeutic approach for breast cancer but also suggest that PMCAs are possible drug targets. 
Alternatively, inhibitors of the PMCA may act as adjuvants to augment the efficacy of other 
anti-neoplastic agents like tamoxifen that have been shown to modulate Ca2+ signaling. Since 
the discovery of a new family of primary active Ca2+ transporters, which are related to 
PMCAs, the opportunities in this field of research are very promising. 
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CHAPTER ONE 
LITERATURE REVIEW 
 
1.1 Introduction 
Free ionized calcium (Ca2+) as an intracellular messenger is indispensable for 
biological processes that encode both life and death [1, 2]. Ca2+ pumps or ATPases are crucial 
components of a cell’s intracellular Ca2+ homeostasis and signaling repertoire [3-5]. The 
plasma membrane Ca2+-ATPase (PMCA) is essential for maintaining a very low resting free 
intracellular Ca2+ concentration [3, 6, 7]. It actively transports with high affinity intracellular 
Ca2+ from the cytosol across the plasma membrane to the extracellular milieu [6-8]. The 
PMCA, however, is not just a trivial mechanism for the extrusion of Ca2+ from a cell’s 
interior. Different PMCA isoforms regulate diverse yet vital physiological functions, for 
instance from hearing to male fertility [9-11]. It is therefore not surprising that alterations in 
PMCA isoforms are associated with various pathophysiological conditions and diseases, for 
example in the form of hypertension, diabetes and even multiple sclerosis [12, 13].  
 
Altered PMCA isoform expression is also implicated in neoplastic diseases, including 
mammary gland tumors [14, 15]. Furthermore, PMCA isoforms are co-ordinately and 
dynamically expressed in the mammary gland during pregnancy and lactation [16, 17]. The 
mammary gland is subjected to tremendous Ca2+ loads during lactation in order to support the 
demands of Ca2+ enrichment into milk [18-20] and new evidence suggests that PMCA-
mediated Ca2+ transport is a major pathway for supplementing the secretion of milk Ca2+ [21]. 
Regulation of PMCA isoform expression is therefore likely to be a fundamental determinant 
of mammary gland Ca2+ homeostasis during lactation. Yet despite accumulating data 
supporting the importance of PMCA-mediated Ca2+ transport in milk Ca2+ enrichment, there 
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is a lack of understanding of the potential roles of PMCA isoforms in regulating other cellular 
processes in the mammary gland, such as epithelial cell proliferation, differentiation and 
apoptosis. Disruptions in PMCA isoform expression may alter PMCA-mediated physiological 
functions in the normal human breast and lead to pathological consequences in the form of 
breast cancer [15]. 
 
It is therefore hypothesized that the regulation of PMCA isoform expression is altered 
in disease states such as breast cancer. Furthermore, PMCA isoforms in the mammary gland 
are proposed to have important consequences in terms of intracellular Ca2+ homeostasis and 
cellular functions, other than mediating Ca2+ transport into milk, in controlling mammary 
gland epithelial cell proliferation, differentiation and apoptosis. These hypotheses have 
important implications in terms of evaluating PMCA isoforms as possible drug targets or 
biological markers in the management of breast cancer. 
 
1.2 Calcium: more that just teeth and bones 
Ca2+ is promoted in popular media sources as an important nutritional element because 
Ca2+ crystallized as Ca2+ hydroxyapatite is a major structural component of teeth and bones 
[22]. Ca2+ also plays a role in other innumerable indispensable biological processes, for 
example fertilization, embryonic development, differentiation, proliferation, muscle 
contraction, metabolism, gene transcription and cell death just to name a few [1, 2, 23-25]. 
However, it is Ca2+ existing as free ionized Ca2+ and acting as a ubiquitous intracellular 
second messenger, not crystallized Ca2+, that mediates these aforementioned essential 
biological processes [1, 2, 22-24].  
 
The question that has continued to baffle physiologists since Sidney Ringer’s 
discovery that isolated rat hearts required the addition of Ca2+ salts to its suspension medium 
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to maintain contraction, is how can one element control so many diverse yet vital biological 
functions [24, 26]? Firstly, for Ca2+ to act as a universal and versatile intracellular second 
messenger, free cytosolic or intracellular Ca2+ concentration ([Ca2+]i) must be able to be 
specifically and dynamically regulated [2, 22]. Secondly, rapid and biologically significant 
fluctuations in [Ca2+]i over a wide concentration range are only possible if background or 
resting [Ca2+]i is kept very low [2, 22]. Thirdly, changes in [Ca2+]i must be able to be detected 
with specificity and sensitivity to translate these intracellular signals into biological outcomes 
[1, 2, 23]. To achieve these three fundamental prerequisites of Ca2+ homeostasis and 
signaling, the cell has at its disposal a multitude of proteins that specifically and reversibly 
bind Ca2+ with the required affinity to modulate [Ca2+]i and also sense Ca2+ signals so that 
they can be processed and transmitted into cellular effects [1, 2, 23]. As well as affording 
flexibility in terms of signal amplitude variation, the versatility of Ca2+ signaling is also 
encoded by diversity in the temporal and spatial characteristics of Ca2+ signals [1, 23]. The 
flexible coordination chemistry characteristics of Ca2+, allowing it to be complexed 
specifically and tightly by irregular structures found in proteins, also support the evolutionary 
choice of Ca2+ over magnesium (Mg2+) as the universal divalent cationic intracellular 
messenger [27]. 
 
Ca2+ signaling regulates almost every conceivable cellular process and is thus essential 
for normal physiology and life. Please refer to Table 1.1 for a list of just some of the functions 
modulated by free ionized Ca2+. However, the versatility of Ca2+ as a universal intracellular 
messenger carries with it an inherently dangerous risk, in that uncontrolled Ca2+ handling can 
lead to toxic intracellular Ca2+ overload and cellular demise [28]. Tightly controlled Ca2+ 
homeostasis and signaling is therefore essential for the maintenance of physiology, health and 
life. The flip side is that uncontrolled Ca2+ homeostasis and signaling can contribute to 
pathophysiology, disease and even death. Abnormal Ca2+ homeostasis and deregulated Ca2+ 
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signaling is involved and has also been implicated in the pathophysiology of many disease 
states, such as Alzheimer’s disease, diabetes, heart failure and also colon, prostate and breast 
cancer [23, 29-40]. This dichotomy is a defining characteristic of Ca2+ signaling and as such, 
the fidelity of its control by proteins that regulate [Ca2+]i or translate Ca2+ signals into cellular 
effects determines whether a cell lives or dies.  
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Table 1.1. A selection of the numerous and essential cellular processes that are modulated by 
free ionized Ca2+. 
Ca2+-modulated cellular processes Reference(s) 
Protein phosphorylation and dephosphorylation  [41, 42] 
Sperm motility [10, 11] 
Cell differentiation  [43-47] 
Secretion of hormones and neurotransmitters [48-50] 
Glycogen metabolism [51, 52] 
Skeletal and cardiac muscle contraction [53] 
Protein synthesis and proteolytic processing [54-56] 
Gene transcription [57-59] 
Cell cycle progression [60-62] 
Cell death: necrosis and apoptosis [28, 40, 63-65] 
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1.3 The basics of Ca2+ homeostasis and signaling 
Ca2+ is able to act as a ubiquitous intracellular second messenger by virtue of the fact 
that [Ca2+]i can be specifically and reversibly regulated inside cells with tight homeostatic 
control [2, 24, 25]. This specificity and reversibility in regulating Ca2+ signals is possible by 
way of combining the expression of various proteins from what Michael Berridge and co-
workers have termed the “Ca2+ signaling toolkit” [1, 23]. Components of this toolkit can be 
grouped into two basic groups, proteins that are involved in controlling [Ca2+]i and thus in 
generating Ca2+ signals and proteins that decode or process these Ca2+ signals [1, 2, 23-25]. 
From this Ca2+ signaling toolkit, the expression of Ca2+ signaling proteins, which includes 
various isoforms and splice variants, can be tailored to suit the temporal and spatial Ca2+ 
signaling requirements of particular cells [1, 23]. 
 
In the resting cell, [Ca2+]i is kept very low at approximately 100 nM, primarily by 
active Ca2+ transporters that either extrude Ca2+ across the plasma membrane to the 
extracellular environment or uptake Ca2+ into intracellular organelles [1, 22]. In contrast, free 
extracellular Ca2+ concentration is at least 10,000-fold higher at around 1-2 mM [1, 22, 66]. 
There exists therefore, a steep electrochemical gradient that would otherwise drive the 
tendency for extracellular Ca2+ to infiltrate cells were it not for the general impermeable 
nature of the plasma membrane to Ca2+ [22]. A Ca2+ signal, which can be exemplified by a 
Ca2+ transient, is induced when [Ca2+]i is elevated beyond its resting concentration (Fig. 1.1). 
Mechanisms for increasing [Ca2+]i to activated concentrations of 1 µM or higher include the 
entry of extracellular Ca2+ via Ca2+ channels in the plasma membrane (voltage-operated Ca2+ 
channels, receptor-operated Ca2+ channels and store-operated Ca2+ channels) or the release of 
stored Ca2+ from intracellular organelles via Ca2+ channels in internal membranes (inositol-
1,4,5-trisphosphate receptors and ryanodine receptors) [1, 2, 23, 25]. 
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Figure 1.1. A hypothetical example of a Ca2+ transient induced by the purinergic receptor 
agonist ATP. Note an increase in [Ca2+]i due to intracellular Ca2+ release from internal stores 
and a decrease in [Ca2+]i after reaching a peak most likely via intracellular Ca2+ efflux and re-
sequestration.  
 
Store-operated Ca2+ channels, also known as capacitative Ca2+ entry (CCE) channels, open in 
response to depletion of intracellular Ca2+ stores and controversially are possibly composed of 
members of the transient receptor potential (TRP) ion-channel family [67, 68]. Inositol-1,4,5-
trisphosphate receptors (IP3Rs) and ryanodine receptors (RyRs) are localized within the 
membranes of the sarcoplasmic reticulum (SR) or endoplasmic reticulum (ER) and are 
activated by Ca2+ itself in a process known as Ca2+-induced Ca2+ release, as well as being 
modulated by the second messenger Ca2+-mobilizing agents inositol-1,4,5-trisphosphate (IP3) 
and cyclic adenosine diphosphate ribose (cADPr), respectively [1, 2, 23, 25]. The discovery 
of IP3 by Michael Berridge and colleagues as a major Ca2+-mobilizing messenger in many cell 
types was a major breakthrough in the field of Ca2+ signaling [69]. Many stimuli act via G-
protein-coupled or tyrosine-kinase-linked receptors on the cell surface, to activate 
phospholipase C (PLC), leading to the hydrolysis of phosphatidylinositol-4,5-bisphosphate 
(PIP2) and the generation of IP3 [1, 23]. A stylized diagram of some the main regulators of 
Ca2+ signaling in mammalian cells is shown in Fig. 1.2 and is described in more detail below.  
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Figure 1.2. A selection of P-type Ca2+-ATPases, Ca2+ exchangers, Ca2+ channels and Ca2+-
binding proteins that regulate Ca2+ signaling in mammalian cells. Note that the stoichiometry 
of Ca2+ and H+ ion counter-transport for the PMCA has been reported to vary. Figure adapted 
from reference [24]. 
 
Elevated [Ca2+]i generates an intracellular Ca2+ signal that is modulated and decoded 
by the action of Ca2+-binding proteins that modify and transduce the message to regulate 
cellular processes [1, 2, 23, 25]. Ca2+-binding proteins include cytosolic Ca2+ buffers, for 
example parvalbumin, which can control the duration and localization of Ca2+ signals [70]. 
Other Ca2+-binding proteins primarily act to translate Ca2+ signals into cellular effects by 
passing on the decoded message to mediators of Ca2+-modulated processes, thus they can be 
referred to as Ca2+ sensors or Ca2+-modulated proteins [2, 25]. The most extensively studied 
Ca2+ sensor is calmodulin, a member of the EF-hand family of proteins [2]. Calmodulin’s four 
EF-hands bind Ca2+ in response to an increase in [Ca2+]i and this induces a conformation 
change that allows the Ca2+-modulated protein to bind and activate various downstream target 
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proteins, thus decoding the Ca2+ signal and transmitting it to effectors [71]. Other non-EF-
hand Ca2+-modulated proteins translate the intracellular Ca2+ signal directly by triggering 
cellular processes once Ca2+ is bound. Protein kinase C (PKC) for example, is able to 
phosphorylate cellular proteins once activated with bound Ca2+, processing a Ca2+ signal 
directly into a cellular response [2].  
 
Once Ca2+ has served its signaling function, [Ca2+]i is lowered to resting levels to 
maintain intracellular Ca2+ homeostasis. Ca2+ is either sequestered into intracellular organelles 
by pumps such as the sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA) or is extruded to 
the extracellular environment by the PMCA or secondary active transporters such as the 
sodium (Na+)/Ca2+ exchanger (NCX) of the plasma membrane [1, 2, 23, 25]. Mitochondria 
are important organelles for sequestration of intracellular Ca2+ via the mitochondrial Ca2+ 
uniporter that is located in the inner mitochondrial membrane and is driven by the negative 
electrical potential across this membrane [72], although its role in regulating global 
intracellular Ca2+ levels appears to vary depending on stimuli and cell type [73, 74]. 
Mitochondrial uptake of Ca2+ may assist temporarily in preventing excessive increases in 
[Ca2+]i that may induce cell death, by rapidly sequestering Ca2+ during periods of intense Ca2+ 
signaling [2]. When signaling has ceased, Ca2+ can then be released back slowly from 
mitochondria to the cytosol via the mitochondrial NCX, for uptake into the ER or extrusion 
from the cell’s interior [2]. The Golgi apparatus, which sequesters intracellular Ca2+ and 
modulates Ca2+ signals via the action of the secretory pathway Ca2+-ATPase (SPCA), has also 
been recognized in recent times as another organelle vital for intracellular Ca2+ homeostasis 
[4, 75-77]. 
 
Although the fundamental characteristics of Ca2+ signals seem simple, complexity 
arises when the spatio-temporal aspects of Ca2+ signaling are considered. Ca2+ transients can 
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be highly compartmentalized within specific areas of the cell from which the signal was 
generated to create microdomains of Ca2+ signaling [1, 2, 23, 73, 78]. For instance, an 
elementary Ca2+ signal occurs when clusters of Ca2+ channels within the ER membrane open 
to form a highly concentrated pulse of Ca2+ around the cytosolic end of the channels, which 
then diffuses rapidly after closure [1, 2, 23]. These elementary events, termed Ca2+ “puffs” or 
“sparks” depending on whether they originate from IP3Rs or RyRs, respectively, can either 
activate localized processes like exocytosis that respond to pulses of Ca2+ generated by 
specific domains of Ca2+ channels or be combined to set up global Ca2+ signals in the form of 
intracellular and intercellular Ca2+ waves via the process of Ca2+-induced Ca2+ release and gap 
junctions [1, 2, 23]. Some processes like muscle contraction require only short Ca2+ signaling 
events in the form of Ca2+ transients in the millisecond range [1, 23]. Other processes like 
transcription and cell proliferation are regulated by long-term Ca2+ signaling events in the 
form of repetitive Ca2+ transients or Ca2+ oscillations that persist in the range of minutes to 
hours [1, 23]. Ca2+ oscillations are an elegant means for cells to undergo long periods of Ca2+ 
signaling without suffering from extended elevations in [Ca2+]i, which may precipitate cell 
death [2]. Frequency and amplitude modulation of Ca2+ oscillations has received particular 
interest and creates an avenue by which cells specifically respond to changes in stimuli and 
differentially regulate cellular processes. For example, changes in the frequency or amplitude 
of Ca2+ signals can mediate the selective activation of distinct transcription factors [57, 58]. 
Frequency modulation of intracellular Ca2+ oscillations can also optimize the efficiency of 
gene transcription such that it is greater at a given oscillation frequency than at alternative 
frequencies [59]. The “shaping” of Ca2+ oscillations therefore represents a subtle way by 
which Ca2+ signaling specifically controls many cellular processes.  
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1.4 The challenge for Ca2+ transport and homeostasis in the mammary 
gland 
Ca2+ signaling has been studied extensively in organs and specialized cells such as the 
liver, heart, skeletal muscle, pancreatic acinar cells and neurons [49, 50, 53, 79, 80]. However, 
the roles and regulation of Ca2+ signaling in the mammary gland and mammary gland 
epithelial cells has historically received much less attention. This is despite the fact that milk 
is rich in Ca2+ [81-84].  
 
The mammary gland or human breast is a unique organ in terms of its sequence and 
induction of development. Breast development is a continual process of modeling and 
remodeling that begins before birth and continues on into menopause in female persons [85-
88]. Prominent changes in the breast architecture are initiated at puberty with growth in both 
glandular and surrounding stromal tissue, however, the breast only attains complete 
morphological and functional differentiation with a full-term pregnancy [85-88]. The reader is 
encouraged to consult reviews that deal exclusively with the development of the human breast 
[85-87] or mouse mammary gland [88] for an in depth description of this process. 
 
The profound changes that occur in mammary gland morphology and function during 
pregnancy and lactation prepare the breast to undertake its primary physiological role, which 
is the production and secretion of milk [85, 88]. The mammary gland can extract large 
quantities of Ca2+ from plasma during lactation, to ensure that milk is concentrated with 
sufficient Ca2+ and thus support the calcification of teeth and bones in the growing neonate 
[18-20, 89]. However, limited studies have addressed the mechanisms involved in the 
transport of maternal plasma Ca2+ into milk [16, 17, 21, 90].  
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Ca2+ is secreted into milk as free ionized Ca2+, Ca2+ bound to citrate or phosphate and 
as Ca2+ complexed with milk caseins [19, 20, 91]. Ionized Ca2+ concentration within human 
milk is approximately 3 mM, total milk Ca2+ concentration is around 8 mM [20, 84], whereas 
total plasma Ca2+ concentration, of which half is ionized, is 3 mM [22]. The mammary gland 
is required to undertake a formidable task during lactation in terms of handling large amounts 
of Ca2+, a process that overall is presumably an active one due to the requirements of Ca2+ 
transport from plasma into milk across mammary gland epithelia against a concentration 
gradient. Thus, the regulation of Ca2+ homeostasis in the breast, particularly the lactating 
mammary gland, is anticipated to be under strict control and placed under exceptional 
demands.  
 
Maintaining Ca2+ homeostasis in the mammary gland is also important so that Ca2+ 
can serve its signaling role while preventing potentially lethal rises in intracellular Ca2+ but at 
the same time Ca2+ fluxes must be of substantial magnitude to enrich milk with enough Ca2+ 
for neonatal needs [19]. Regulation of Ca2+ homeostasis and signaling in the breast is also 
likely to have cellular and physiological consequences other than the transfer of sufficient 
Ca2+ into milk during lactation, for example effects on mammary gland epithelial cell 
proliferation, differentiation and apoptosis that in turn may affect glandular architecture and 
post-lactational involution. Regulation of Ca2+ transport and signaling in the mammary gland 
is therefore expected to be presented with unique challenges throughout the continuum of 
breast development. To achieve this, the mammary gland is likely to dynamically and co-
ordinately express a multitude of Ca2+ signaling regulators, of which Ca2+ pumps probably 
play a prominent role.  
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1.5 Ca2+ pumps: crucial participants in Ca2+ homeostasis 
Active Ca2+ transporters of mammalian cells are pumps or exchangers that reside in 
both the plasma and internal membranes to reversibly and specifically regulate the 
concentration of Ca2+ within the cytosol and other organelles [2, 23, 25]. They include 
transporters of the plasma membrane such as the PMCAs and NCXs, as well as the SERCAs 
and SPCAs, which reside in the membranes of the sarco(endo)plasmic reticulum and the 
Golgi apparatus, respectively [2, 23, 25]. The Ca2+ needs of individual cells appear to 
determine the types of active Ca2+ transporters required in that cell. For example, in excitable 
cells such as cardiac cells, which frequently undergo high elevations in [Ca2+]i, the large 
capacity but low affinity NCXs are likely to be the predominant mechanism for Ca2+ efflux 
[2, 25, 92]. Whereas in some non-excitable cell types (for example pancreatic and parotid 
acinar cells) [93, 94], the PMCA is the main modulator of Ca2+ extrusion. Nevertheless, even 
in excitable cells such as neurons, PMCAs are envisaged to be important modulators of Ca2+ 
efflux by being the major mechanism for the recovery of resting [Ca2+]i after minor Ca2+ 
elevations [95, 96]. PMCAs are low capacity yet high affinity mechanisms for the extrusion 
of free intracellular Ca2+, which are able to function at low levels of [Ca2+]i to maintain resting 
[Ca2+]i and overall intracellular Ca2+ homeostasis [6, 7, 97, 98]. PMCAs, along with SERCAs 
and SPCAs are P-type ion-motive ATPases that are ideally suited to translocating Ca2+ against 
large Ca2+ gradients, since they are all primary active transporters [3, 4, 8, 75, 76]. P-type 
ATPases are named accordingly because the transfer of a phosphate group from adenosine 
triphosphate (ATP) leads to the formation of an energized aspartyl-phosphate intermediate 
that is coupled to ion translocation during the reaction cycle [3, 8]. Together, these P-type 
Ca2+-transporting ATPases are likely to be the major pathways for lowering [Ca2+]i in 
mammary gland epithelial cells and due to the high demand for Ca2+ translocation from 
plasma to milk during lactation, they may also be important regulators of macro-Ca2+ 
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homeostasis in the mammary gland [16, 17, 21], as well as being possible mediators of other 
cellular processes that are relevant to mammary gland physiology and pathophysiology.  
 
1.6 The physiological importance of PMCA isoforms and splice variants 
It is widely acknowledged that there are four mammalian PMCA isoforms 
(PMCA1−PMCA4), which are encoded by four different genes (ATP2B1−ATP2B4) on 
separate chromosomes [3, 5, 7, 99]. Human PMCA isoforms are located on the following 
chromosomes: 12 for PMCA1, 3 for PMCA2, X for PMCA3 and 1 for PMCA4 [3, 5, 7, 99]. 
Alternative splicing of primary transcripts also gives rise to additional PMCA isoform 
diversity [3, 5, 7, 99]. However, this diversity in potential PMCA expression questions the 
physiological importance of PMCA isoforms and splice variants. In other words, what are the 
functions of different PMCA isoforms and splice variants in the context of Ca2+ signaling and 
the control of cellular processes that are important for normal physiology? PMCA isoforms 
and splice variants also display differences in terms of biochemical regulation of activity and 
whether they are targeted to reside in different regions of the plasma membrane [5-7, 97, 98, 
100-103]. These differences in the biochemical properties and localization of PMCA isoforms 
and splice variants may at first seem trivial. However, when they are reconciled with evidence 
that PMCAs are able to modulate Ca2+ signaling as well as contribute to compartmentalized 
Ca2+ signals, it suggests that the expression of particular PMCA isoforms and splice variants, 
coupled with their differences in terms of biochemical regulation and localization, is matched 
to meet the unique Ca2+ signaling requirements of divergent cell types and thus support 
different physiological roles. 
 
These next sections on PMCA isoforms and splice variants will therefore look at 
tissue distribution and some of the gene knockout or knockdown approaches that have been 
used to elucidate the physiological roles of specific PMCA isoforms in different model 
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systems. It will also briefly look at the biochemical differences between PMCA isoforms, as 
well as the differences in PMCA localization. The role of PMCA isoforms as modulators of 
the dynamics of Ca2+ signaling and the versatility afforded by these differences between 
PMCA isoforms in contributing to specialized physiological demands of particular cells will 
then be addressed.  
 
1.6.1 PMCA isoform tissue distribution 
The expression of PMCA isoforms and splice variants exhibit differential distribution 
depending on tissue or cell type [99]. PMCA alternative splicing in vivo occurs at two major 
sites, splice sites A and C, whereas splice site B is believed to be a splicing artefact [99]. 
PMCA1 is found in all tissue types and is commonly referred to as a “house-keeping” isoform 
[98, 99]. PMCA4 also has a wide tissue distribution and is designated as another “house-
keeping” isoform [98, 99]. The other PMCA isoforms display restricted tissue distribution. 
For example, PMCA3 is present in the brain, spinal cord and fetal skeletal muscle [99] while 
PMCA2 is found in the heart, brain [99] and the mammary gland of lactating rats [16, 17]. 
The use of isoform-specific antibodies that can also detect alternative splice variants has 
shown that in the rat brain, the PMCA4b variant is expressed in all regions examined, 
however, PMCA4a is only detectable in the frontal cortex [104]. Furthermore, rat RINm5F 
pancreatic β-cells only express PMCA4b mRNA, whereas in rat islets of Langerhans, which 
in addition to β-cells also contain non-insulin-secreting cells, both PMCA4a and PMCA4b are 
detectable [105]. PMCA isoforms in the developing mouse are also dynamically and spatially 
expressed [106]. It has therefore been suggested that the expression of different PMCA 
isoforms and splice variants is tailored to support the physiology of diverse cell types and 
tissues [98, 99, 107, 108].  
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1.6.2 PMCA gene knockout and knockdown studies 
Gene manipulation approaches to either knockout or knockdown PMCA gene 
expression are progressively beginning to reveal the functional importance of PMCA 
isoforms in regulating different cellular and physiological processes [9-11, 21, 43, 102]. For 
example, the finding that PMCA2-null mice are deaf and have an unsteady gait suggests that 
PMCA2 is required for both hearing and balance [9]. PMCA2 is likely to be a major 
mechanism of Ca2+ extrusion in the endolymph of the vestibular system required for the 
formation of otoconia, which are Ca2+ carbonate crystals that act as physical sensors of 
gravity and acceleration [9]. Additionally, the male PMCA4-null mice are infertile, not due 
defects in sperm morphology but due to impaired sperm motility [10, 11]. The finding that 
PMCA4 is highly localized in the sperm tail of wild-type male mice is particularly interesting 
because it indicates that PMCA4-mediated Ca2+ extrusion in this region of the sperm is 
crucial for the motility of this specialized cell type [10, 11]. PMCA1-null mutations on the 
other hand cause embryolethality, thus signifying that PMCA1 is the major house-keeping 
isoform that is also essential for embryonic development [11]. For more information on 
PMCA knockout studies please see the following references [109, 110]. 
 
1.6.3 Regulation of PMCA activity and localization: differences between isoforms and 
splice variants 
PMCA activity is subjected to multiple modes of biochemical regulation, the 
sensitivity to which differs amongst PMCA isoforms and splice variants [5-7, 97-100]. For 
reviews describing historical approaches to the study of PMCA biochemistry in the purified 
state, please refer to the established work of Ernesto Carafoli [6, 7]. Of all PMCA isoforms, 
PMCA2 has the greatest affinity for calmodulin, which has been the most extensively studied 
activator of the PMCA pumping function [111-114]. In the unstimulated state, the 
calmodulin-binding domain located on the C-terminal cytosolic tail of the PMCA mediates 
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PMCA autoinhibition by binding to two intramolecular “receptor” sites within the transporter 
[3, 8, 99]. This autoinhibitory interaction is likely to restrict ATP binding and access to Ca2+ 
for translocation [115]. When intracellular Ca2+ is elevated to form complexes with 
calmodulin, the interaction between Ca2+-bound calmodulin and the calmodulin-binding 
domain of the PMCA relieves this autoinhibition to stimulate the pump [3, 8, 99]. PMCA2 
also has a higher affinity for Ca2+ than PMCA4, in addition to having a higher level of basal 
activity (in the absence of calmodulin) [112]. This suggests that cells expressing abundant 
amounts of PMCA2 may have a lower resting [Ca2+]i and are also able to respond to even 
small elevations in [Ca2+]i [98, 108]. Alternative splicing at splice site C located within the 
calmodulin-binding domain is also known to influence PMCA regulatory properties [99]. For 
instance, the PMCA4b variant has a higher affinity for calmodulin than PMCA4a and 
therefore also has a higher apparent affinity for Ca2+, which would imply that PMCA4b would 
start pumping at a [Ca2+]i lower that what would be required for PMCA4a activation [116]. 
PMCA isoforms and splice variants therefore have different biochemical properties in terms 
of their regulation by calmodulin. PMCAs can also be activated by a variety of other 
mechanisms, for example by acidic phospholipids, protein kinases, self-association 
(oligomerization) and proteolytic cleavage of the autoinhibitory calmodulin-binding domain 
by proteases such as calpain to generate a constitutively active PMCA fragment [5-7, 97-100]. 
 
In certain cell types, the PMCA is not distributed evenly within the plasma membrane 
but are localized to small flask-like plasma membrane invaginations called caveolae [117, 
118]. Although the physiological significance of PMCA localization to caveolae is uncertain, 
PMCA concentration in caveolae may play a role in facilitating PMCA oligomerization and 
regulation of PMCA activity by acidic phospholipids of the plasma membrane such as PIP2 [3, 
97, 98]. PMCA isoforms and splice variants are also differentially localized to 
morphologically distinct plasma membrane regions in polarized epithelia [101-103]. 
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PMCA4b appears to be the predominant PMCA isoform that is expressed and targeted to the 
basolateral membrane of polarized Madin-Darby canine kidney (MDCK) cells [102]. This has 
important implications in major Ca2+ transporting epithelia that exist for example in the 
kidney, where the directionality of Ca2+ transport is crucial to the physiology of the organ. 
The diversity of PMCA isoforms and splice variants, coupled with their differences in relation 
to biochemical regulation and localization thus provides a basis by which cells and organs can 
flexibly adapt their expression of PMCAs to suit particular Ca2+ signaling and physiological 
requirements. 
 
1.6.4 PMCAs as modulators of the dynamics of Ca2+ signaling 
The primary biochemical role of PMCA isoforms as transporters for the extrusion of 
intracellular Ca2+ may at first imply that they are merely multiple mechanisms for lowering 
elevated [Ca2+]i and preserving a low resting [Ca2+]i. There is evidence, however, that PMCAs 
modulate the dynamics of Ca2+ signaling and therefore the shape of Ca2+ signals [119-125]. 
For example, overexpression of PMCA1a in rat aortic endothelial cells lowers peak 
intracellular Ca2+ responses induced by ATP [119]. Similarly, overexpression of PMCA4 in 
Chinese Hamster Ovary (CHO) cells decreases both the amplitude and duration of ATP-
induced intracellular Ca2+ responses [120].  
 
The PMCA also appears to have an important role in shaping the typical biphasic 
kinetic profile of a CCE transient [121-123]. In bovine pulmonary artery endothelial cells and 
Jurkat human leukemic T cells, a delayed increase in the activity of the PMCA shapes the 
formation of a biphasic Ca2+ signal induced during CCE, that is characterized by an initial 
overshoot in [Ca2+]i followed by a slow decrease in [Ca2+]i to a plateau [121-123]. PMCA 
inhibition abolishes this secondary decay phase of a CCE transient [121, 122]. The decay 
phase of Ca2+ transients have also been reported to be modulated by both glucocorticoids and 
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the immunosuppressant cyclosporine A via a PMCA-mediated mechanism [124, 125]. 
Interestingly, PMCA2 has a higher rate of activation by Ca2+/calmodulin than PMCA4, 
suggesting that the speed at which peak intracellular Ca2+ transients decay is faster in cells 
expressing PMCA2, compared to other PMCA isoforms with a lower rate of activation [126].  
 
PMCAs are also implicated in the control of compartmentalized Ca2+ fluctuations, 
localized for example just within or outside the plasma membrane [97, 127, 128]. This 
supposition is supported by data demonstrating that manipulation of the plasma membrane 
microdomain Ca2+ concentration gradient by elevating extracellular Ca2+ enhances rates of 
PMCA-mediated Ca2+ extrusion during CCE, without major changes in global [Ca2+]i [127]. 
The PMCA has furthermore been suggested to mediate localized increases in extracellular 
Ca2+ concentration just outside the plasma membrane and in turn potentiate intracellular Ca2+ 
signals induced by extracellular agonists [128]. The totality of these studies therefore 
indicates that PMCAs are influential participants in contributing to the spatio-temporal 
versatility of Ca2+ signaling and is of particular functional relevance given that subtle changes 
in Ca2+ signal oscillation frequency or amplitude can mediate selective transcription factor 
activation [57, 58].  
 
1.7 Regulation of PMCA gene expression  
The functional expression of genetic information by the transcription of ribonucleic 
acid (RNA) from deoxyribonucleic acid (DNA), followed by the translation of RNA into 
protein is an essential cellular process that governs the biology of all living organisms; a 
universal principle that has been designated as the central dogma of molecular biology [129]. 
Different cell types in a multicellular organism, despite possessing the same genome, express 
different sets of messenger RNA (mRNA) and protein to support their defined physiological 
roles [130]. Although there is a wealth of information regarding the regulation of PMCA 
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activity, little is know about the regulation of PMCA isoform and splice variant gene 
expression. This has primarily been due to the traditional approaches that have been used to 
study biochemical regulation of PMCA activity of either the purified or reconstituted protein 
[6, 7]. This void in our knowledge of mechanisms that regulate PMCA isoform gene 
expression also still remains despite the fact that PMCA isoforms are differentially expressed 
depending on tissue or cell type [99]. There is also evidence that transcriptional regulation is a 
major means for the control of PMCA isoform gene expression, so that diverse cell types can 
adapt their needs for Ca2+ transport to suit their unique functions, under different 
physiological situations and extracellular cues. This next section will therefore look at 
regulation of PMCA gene expression as an important mechanism for supporting the Ca2+ 
signaling requirements of specialized cells under changing physiological demands, as well as 
the suggestion that Ca2+ itself may regulate PMCA gene expression as part of a feedback 
loop. 
 
Indications that dynamic regulation of PMCA expression, rather than PMCA activity, 
is of biological significance in response to changing physiological needs were initially 
obtained from studies looking at intestinal Ca2+ absorption [131-134]. Vitamin D, the active 
form of which is known as 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), is an important 
hormone involved in facilitating intestinal Ca2+ uptake and overall systemic Ca2+ homeostasis 
[135]. Treatment of vitamin D-deficient chickens with 1,25(OH)2D3 increases duodenal 
PMCA mRNA levels in a time-dependent manner [131]. Duodenal PMCA mRNA expression 
is also elevated in chickens on a low Ca2+ diet [131]. Comparisons between nuclear and total 
cellular levels of duodenal PMCA mRNA in vitamin D-deficient chickens suggests that 
1,25(OH)2D3 modulates PMCA expression by increasing transcription [132]. PMCA1 is the 
predominate isoform present in the small intestine [133]. PMCA1 transcripts are also more 
abundantly expressed in proximal small intestinal segments that are implicated to have a 
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greater contribution to dietary Ca2+ absorption, such as the duodenum, compared to distal 
segments like the jejunum or ileum [134].  
 
Data demonstrating modulation of PMCA mRNA and protein levels by 1,25(OH)2D3 
additionally substantiate the notion that regulation of PMCA gene expression is important for 
the physiology of the kidney [102, 136, 137]. PMCA1b, PMCA2b and PMCA4b transcripts 
are detectable in polarized MDCK cells, an immortalized cell line representing distal kidney 
tubules [102]. PMCA1, PMCA2 and PMCA4 are all expressed at the protein level, however, 
PMCA4 is the predominant isoform that is localized to the basolateral membrane, which 
would ordinarily be facing the plasma, of polarized MDCK cells [102]. 1,25(OH)2D3 
increases both PMCA4 mRNA and protein expression in polarized MDCK cells, as well as 
elevating PMCA4 protein levels in the basolateral membrane [136]. Functionally, 
1,25(OH)2D3 enhances apical to basolateral flux of radioactive Ca2+ in tight monolayers of 
polarized MDCK cells, indicating that positive regulation of PMCA4 expression is an 
important homeostatic mechanism that mediates increased transcellular renal reabsorption of 
Ca2+ from urine in response to vitamin D. 1,25(OH)2D3 also increases PMCA1 expression in 
MDCK cells and in another cell line representing a distal kidney tubule model [136, 137], 
however, the relative effects of increased PMCA1 and PMCA4 expression in contributing to 
vitamin D-induced upregulation of renal transcellular Ca2+ transport is uncertain.  
 
In addition to the changes in PMCA expression that occur to assist in systemic Ca2+ 
homeostasis, as in the case of intestinal Ca2+ absorption or renal Ca2+ reabsorption, regulation 
of PMCA isoform gene expression also appears to tailor the rigorous Ca2+ signaling 
requirements of specialized cells subjected to changes in physiological stimuli or 
circumstances. For instance, glucose stimulation of rat pancreatic islet cells decreases PMCA 
expression while increasing NCX expression, indicating that insulin release upon blood 
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glucose elevation is facilitated by a regulatory switch that induces the expression of a high- 
capacity Ca2+ extrusion mechanism to replace a low-capacity one in pancreatic β-cells [138]. 
Furthermore and as discussed below, dynamic expression of PMCA isoforms in the rat 
mammary gland appears to be an important physiological phenomenon of pregnancy and 
lactation [16, 17, 21]. There is also gathering evidence that PMCA isoform expression is 
subjected to deregulation by pathophysiological stimuli and certain disease processes. For 
instance, overexpression of PMCA4 has been implicated in increased vascular reactivity and 
hypertension [139], whereas PMCA1 expression is repressed by corticosterone and chronic 
cold stress in the rat hippocampus [140]. Interestingly, reduced spinal cord PMCA2 levels 
have been linked to multiple sclerosis [141]. Similarly, PMCA-2 null mice display reduced 
motor neuron numbers in the spinal cord [13]. Dynamic expression of PMCA isoforms is 
therefore likely to represent a major means for controlling normal physiological processes, 
such that deregulation of this control may have pathophysiological ramifications.  
 
A concept that has begun to arise in this area of investigation is that Ca2+ signals may 
themselves regulate PMCA isoform gene expression. This would imply that the expression of 
Ca2+ signaling components of different cell types that initiate, modulate and process Ca2+ 
signals are controlled by these very signals as part of a feedback loop [23, 142]. This notion is 
backed up by studies in cultured primary cerebellar granule neurons, whose long-term 
survival and maturation depend on sustained membrane depolarizing conditions that promote 
elevation of [Ca2+]i [143, 144]. Under these conditions, the expression of PMCA1a, PMCA2 
and PMCA3 is upregulated, whereas that of PMCA4a goes down [143]. These effects on 
PMCA isoform gene expression are dependent on Ca2+ influx, since the application of L-type 
Ca2+ channels blockers negated both the upregulation of PMCA1a, PMCA2 and PMCA3 and 
the downregulation of PMCA4a in granule cells grown under depolarizing conditions [143]. 
Furthermore, PMCA4a expression in granule cells seems to be regulated at the level of gene 
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transcription, since inhibition of calcineurin, whose classical down-stream target is the 
transcription factor nuclear factor of activated T cells (NF-AT), abolishes depolarization-
induced downregulation of PMCA4a without affecting the expression of other PMCA 
isoforms [144]. Little is currently know about which particular hormones, specific signaling 
pathways or transcription factors are able to regulate PMCA isoform gene expression but it 
may involve multiple pathways and may be specific to different cell types [145]. For instance, 
angiotensin II increases the expression of PMCA1 mRNA in rat vascular endothelial cells 
from the aorta but not from the brain resistant vessel [145]. Instead, PMCA1 expression in rat 
brain resistant vessel endothelial cells appears to be modulated by the release of stored Ca2+, 
as treatment with thapsigargin, which is a SERCA inhibitor, upregulates PMCA1 mRNA 
[145]. Potential binding sites have also been identified for AP-1, AP-2 and Sp1 transcription 
factors in the PMCA1 promoter from a mouse genomic library [146] and future studies of 
PMCA isoform promoter regions will hopefully clearly elucidate the specific mechanisms of 
PMCA isoform gene regulation in different cell types.  
 
1.8 PMCAs in mammary gland physiology 
The demands of milk Ca2+ enrichment during lactation requires that the mammary 
gland be subjected to large Ca2+ fluxes [89]. However, little is know about the identity and 
regulation of the transport mechanisms that are crucial for the concentration of Ca2+ into milk. 
We know though that mammary gland Ca2+ transport is transcellular, in other words occurring 
across plasma membranes and overall unidirectional [147]. Uncertainty generally exists as to 
the exact mechanisms responsible for the transport of Ca2+ across the basolateral membranes, 
facing the maternal plasma, of secretory mammary gland epithelial cells [19]. Ideally, 
processes for Ca2+ transport across the basolateral membrane of secretory mammary gland 
epithelial cells would have to be of large capacity, unidirectional and inducible, making Ca2+ 
channels likely candidates to perform this role [148]. The nature of the ionized Ca2+ gradient 
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across the basolateral membrane of secretory mammary gland epithelial cells whereby free 
plasma Ca2+ concentration is expected to be around 1-2 mM and resting [Ca2+]i is 
approximately 100 nM would also suggest that Ca2+ channels, which are passive mechanisms 
for Ca2+ transport down its electrochemical gradient, are likely to be major means for the 
extensive transfer of plasma Ca2+ into milk during lactation (Fig. 1.3). In contrast to the 
paucity of knowledge concerning basolateral Ca2+ transport in the lactating mammary gland, 
there is emerging evidence suggesting that P-type Ca2+-ATPases, particularly PMCAs, are 
important mediators of Ca2+ transfer into milk [16, 17, 21]. Once again, due to the nature of 
the ionized Ca2+ gradient across the apical membrane of secretory mammary gland epithelial 
cells whereby resting [Ca2+]i is expected to be 100 nM and free ionized Ca2+ concentration in 
human milk is 3 mM, PMCAs would be ideally suited to directly secreting Ca2+ into milk 
across the apical membrane during lactation because they are primary active Ca2+ transporters 
(Fig. 1.3). 
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Figure 1.3. Transcellular Ca2+ transport in the lactating mammary gland epithelial cell and the 
likely transporters that mediate this process. The overall direction of transcellular Ca2+ 
transport is unidirectional but note the presence of two ionized Ca2+ gradients; one across the 
basolateral membrane and the other across the apical membrane. Lactating PMCA2-null mice 
have deficiencies in milk Ca2+ enrichment and indirect evidence suggests that localization of 
the PMCA2bw isoform is apical in the mammary gland epithelial cell [17, 21]. SPCAs are 
also likely to be important mechanisms of Ca2+ transport during lactation. Basolateral Ca2+ 
transport mechanisms are currently unknown but may involve TRP channels. Figure adapted 
from references [19, 20, 91].  
 
 Aside from a possible physiological role in the direct secretion of Ca2+ into milk, 
PMCAs, particularly PMCA1 and PMCA4, are likely to have other important functions in the 
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breast. Studies in other model systems suggest that specific PMCA isoforms may regulate cell 
proliferation, differentiation and apoptosis in the breast [43, 44, 64, 65, 143, 149-151]. The 
following sections will therefore evaluate the plausibility of PMCAs in supporting Ca2+ 
transfer into milk during lactation as well as look at potential roles for PMCAs in controlling 
other cellular processes such as cell proliferation, differentiation and apoptosis, which also 
contribute to normal mammary gland physiology but are altered in disease states such as 
cancer [85-87, 152, 153].  
 
1.8.1 PMCAs in lactation: a partnership with SPCAs 
The pervasiveness of intracellular Ca2+ as a second messenger along with the unique 
biochemical properties of PMCA isoforms make it easy to accept that PMCAs are primarily 
regulators of intracellular Ca2+ homeostasis and signaling. Studies by Reinhardt and 
colleagues suggest that PMCA isoforms also play important physiological roles in the breast 
beyond the maintenance of intracellular Ca2+ homeostasis and signaling [16, 17, 21]. Overall, 
the induction of lactation appears to generally increase the expression of P-type Ca2+-ATPases 
such as PMCAs and SPCAs in the mammary gland (Table 1.2) [16, 17]. PMCA1b, PMCA4b 
and PMCA2b mRNA transcripts are detectable in the mammary gland of pregnant and 
lactating rats [16]. After parturition and during lactation, total PMCA protein expression is 
upregulated in rat whole mammary gland [17] due to an increase predominately in the 
PMCA2bw splice variant [16, 17]. Indeed, PMCA2 protein expression is increased almost 
100-fold in rat mammary gland by day 18 of lactation, compared to day 11 of pregnancy 
(Table 1.2) [17]. The expression of the PMCA2bw splice variant would particularly suit the 
demands of Ca2+ homeostasis in the mammary gland, since the b splice variant of PMCA2 at 
splice site C has a higher affinity for calmodulin than splice variant a [112] and the w splice 
option at splice site A results in localization of PMCA2 to apical membranes in polarized 
MDCK epithelial cells [103].  
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Table 1.2. P-type Ca2+-ATPase mRNA and protein expression in the pregnant and lactating 
rat mammary gland. Negative days represent days before parturition, whereas positive days 
indicate days of lactation. Table from references [16, 17]. 
 
P-type Ca2+-ATPase Expression during 
pregnancy 
Expression during 
lactation 
PMCA1 mRNA No significant change in 
expression detected during 
pregnancy 
Increases 2-fold by day 18 
of lactation compared to 
day -1 prepartum 
PMCA1 protein  Increases 2-fold by day -1 
prepartum compared to day 
-10 
Increases 2.5-fold by day 
18 of lactation compared to 
day -1 prepartum 
PMCA2 mRNA No significant change in 
expression detected during 
pregnancy 
Increases 50-fold by day 
18 of lactation compared to 
day -1 prepartum 
PMCA2 protein No significant change in 
expression detected during 
pregnancy 
Increases 100-fold by day 
18 of lactation compared to 
day -1 prepartum 
PMCA3 mRNA Not yet characterized 
 
 
Not detected during 
lactation 
PMCA4 mRNA No significant change in 
expression detected during 
pregnancy 
Increases 4.5-fold by day 
18 of lactation compared to 
day -1 prepartum 
PMCA4 protein  Increases 2-fold by day -1 
prepartum compared to day 
-10 
Decreases 16-fold by day 
of 18 of lactation compared 
to day -1 prepartum 
SERCA1 mRNA Not yet characterized 
 
 
Not yet characterized 
 
 
SERCA2 mRNA No significant change in 
expression detected during 
pregnancy  
Increases 2-fold by day 18 
of lactation compared to 
day -1 prepartum 
SERCA3 mRNA No significant change in 
expression detected during 
pregnancy 
Increases 2-fold by day 18 
of lactation compared to 
day -1 prepartum 
SPCA1 mRNA Increases 4-fold by day -1 
prepartum compared to day 
-14 
Increases 1.5-fold by day 
18 of lactation compared to 
day -1 prepartum 
SPCA1 protein  Increases 3-fold by day -1 
prepartum compared to day 
-10 
Increases 2-fold by day 18 
of lactation compared to 
day -1 prepartum 
SPCA2 Not yet characterized 
 
 
Not yet characterized 
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While PMCA2 mRNA levels relative to DNA content in the mammary gland of 
lactating rats are up to four-times higher than in the brain, the brain expresses up to three-
times more PMCA2 protein [17]. Reinhardt and co-workers [17] propose that PMCA2 protein 
in the mammary glands of lactating rats has a shorter half-live than the relatively long half-
live of 12 days for PMCA in the rat brain [154]. PMCA2 protein is secreted into milk and is 
particularly concentrated in milk fat globule membranes, which are derived from the apical 
membrane of secretory mammary epithelial cells [17]. The secretion of milk fat via milk fat 
globule membranes and the subsequent need to replenish apical membranes of secretory 
mammary epithelial cells is likely to account for why PMCA2 mRNA is relatively abundant 
while PMCA2 protein half-life is relatively short, in the lactating rat mammary gland [17]. 
This suggests that PMCA2 protein is localized to the apical surface of secretory mammary 
epithelial cells during lactation and also implies that PMCA2 plays a role in bulk or macro-
Ca2+ homeostasis by concentrating milk with Ca2+ required for lactation [17]. The expression 
of other PMCA isoforms in the mammary gland also appears to change with the induction of 
lactation (Table 1.2). However, although the dynamic regulation of PMCA expression in rat 
mammary tissue demonstrated by Reinhardt et al is most likely to be reflective of PMCA 
expression in mammary gland epithelial cells, which form the ducts and functional alveoli of 
the mammary gland [88], normalization of PMCA expression data relative to an epithelial 
marker like keratin 7 would have provided more confidence in the above results [155]. 
 
Further support for PMCA2’s role in enriching milk with Ca2+ comes from studies 
with lactating female PMCA2-null mice. These mice have a 60 % decrease in milk Ca2+ 
compared to either heterozygous or wild type mice [21]. Milk protein concentration is also 
modestly lower in homozygous and heterozygous PMCA2-null mice when contrasted with 
wild type mice [21]. Since Ca2+ sequestration into intracellular organelles such as the ER and 
Golgi apparatus is important for milk protein synthesis, modification and secretion [156], the 
 29
observed effect on milk protein concentration in lactating PMCA-2 null mice is possibly due 
to the relatively minor loss of Ca2+ accumulation into the Golgi apparatus that may be 
afforded by newly synthesized PMCA2 in transit to the apical membrane of mammary 
epithelial cells [21, 157]. Even though milk Ca2+ concentration values, both uncorrected and 
corrected for milk protein secretion, were demonstrably lower in lactating PMCA2-null mice 
compared to heterozygous or wild-type mice, the physiological consequences of this 
deficiency in terms of absolute milk production and the health of newborn mice are uncertain. 
This is due to the fact that the authors used an indirect measure of milk production by 
comparing litter body weights [21]. Litter weights of PMCA2-null mice are significantly 
lower compared to heterozygous or wild-type mice, however, it is not known whether this is a 
result of reduced milk Ca2+ concentration, changes in overall milk production or alterations in 
nursing ability of PMCA2-null mothers, since these mice are also deaf [21]. Together, these 
studies provide the first direct support for PMCA, specifically PMCA2, having a functional 
role beyond the fine tuning of Ca2+ signals and the maintenance of a low resting [Ca2+]i; the 
extrusion of Ca2+ across the apical membrane of secretory mammary gland epithelial cells to 
concentrate milk in the extracellular alveolar lumen with enough Ca2+ required for lactation. 
PMCA2’s involvement in Ca2+ transport into milk was perhaps unexpected given the 
traditional view that the enrichment of milk with Ca2+ was likely to occur via exocytosis of 
secretory vesicles packaged within the Golgi apparatus, for example as Ca2+ phosphate, Ca2+ 
citrate and as Ca2+ complexed with caseins [19, 20, 91]. This is not to say that the release of 
Golgi-derived secretory vesicles is likely to be a trivial pathway for milk Ca2+ enrichment. 
 
SPCAs are relatively newly discovered members of the P-type family of Ca2+-
ATPases, which have also been implicated in supporting the lactating phenotype [4, 16, 17, 
76]. Two SPCA isoforms, SPCA1 and SPCA2, exist in humans and are localized to Golgi 
complexes [158-161]. A unique property of SPCAs is their ability to transport Ca2+ with high 
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affinity as well as ionized manganese (Mn2+) into the Golgi [160-162]. Knowledge of the 
roles of SPCA isoforms in the mammary gland is extremely limited. Regulation of SPCA1 
may, however, play an essential role in milk production and/or secretion. In the mammary 
gland of pregnant rats, SPCA1 protein expression increases three-fold one week before 
parturition compared to early pregnancy levels [17]. It is then further elevated to be 
approximately six-fold higher throughout lactation (Table 1.2) [17]. The timing of the 
changes in SPCA1 expression observed in periparturient and lactating rats suggests that 
SPCA1 may be upregulated in preparation for extensive and continued mammary gland 
epithelial cell secretory activity required to maintain milk production and/or secretion [17]. 
Indeed, to presumably cope with the extensive demand for Ca2+ by the lactating rat mammary 
gland plasma Ca2+ concentrations drop significantly just before parturition, whereas plasma 
1,25-dihydroxyvitamin D3 (1,25(OH)2D3) levels rise, presumably to correct the resultant 
hypocalcemia via increased gastrointestinal Ca2+ absorption and thus sustain lactation [16]. 
The relative expression of SPCA1 mRNA to DNA in the mammary gland is up to eight times 
higher than in the brain, yet relative SPCA1 protein expression is only marginally higher in 
the mammary gland. Together, this suggests that SPCA1 protein is being turned over at a 
faster rate in the mammary gland than in the brain, although not at the accelerated rate that 
seems to occur for mammary PMCA2 [17]. The dynamic regulation of SPCA1 expression 
appears to be an essential mechanism for homeostatic control of lactation. What functional 
purpose this induction in SPCA1 expression serves in lactation is unknown but maintenance 
of Golgi Ca2+ levels may be important. Compared to resting [Ca2+]i, the steady-state 
intraluminal Golgi Ca2+ concentration of approximately 200 µM in normal keratinocytes is 
relatively high [163]. Similarly, in HeLa cells, resting intraluminal Golgi Ca2+ concentration 
is approximately 300 µM [164]. Luminal Ca2+ accumulation within intracellular organelles is 
important for the secretory pathway by controlling protein synthesis, processing, stability, 
trafficking and secretion [54, 156]. Ca2+ depletion from intracellular organelles such as the 
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Golgi can have deleterious effects on the secretory pathway and indeed Golgi Ca2+ loss 
prevents proteolytic processing of plasma protein precursors [55]. In the mammary gland, 
luminal Ca2+ within the Golgi cisternae may be the source of Ca2+ that regulates the activity 
of membrane-associated intraluminal casein kinases required for casein phosphorylation [54]. 
Caseins are synthesized and secreted by the mammary gland as micelles [165] and casein 
phosphorylation, in conjunction with interactions with Ca2+ phosphate, are important 
determinants of casein micellar structure [54, 165]. Thus, Golgi Ca2+ accumulation in the 
mammary gland may be important in maintaining the structural integrity of casein micelles. 
Another possibility is that Ca2+ accumulation within the Golgi is actually a temporary storage 
place for Ca2+ to be secreted into milk, given that Ca2+ complexed with caseins, phosphate 
and citrate forms major components of total Ca2+ content in milk [82]. SPCA1 upregulation 
concomitant with the start of lactation may give mammary gland epithelial cells an added 
buffer against detrimental rises in [Ca2+]i in an environment undergoing constant Ca2+ fluxes 
of high magnitude.  
 
Whether SPCA2, like SPCA1, is associated with dynamic changes in expression 
during lactation is yet to be addressed, however, its specific tissue distribution and its reported 
expression in mammary gland identifies this P-type Ca2+-ATPase as a target for future 
research. The expression of both SPCA isoforms in the mammary gland is interesting since 
SPCAs can transport both Ca2+ and Mn2+ [17, 160, 161]. If biochemical differences between 
the two isoforms do exist, such that SPCA1 Ca2+ affinity is higher than that of SPCA2 and 
Mn2+ competitively inhibits SPCA-mediated Ca2+ transport [161], Golgi requirements for 
divalent ion accumulation during lactation may be such that SPCA1 supplies Ca2+, whereas 
SPCA2 delivers Mn2+. Casein phosphorylation mediated by casein kinase in vitro is a divalent 
cation dependent process that is stimulated by Ca2+ but it is even more effectively simulated 
by Mn2+ [54]. Furthermore, Mn2+ is required for the activity of galactosyltransferase, which is 
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a Golgi-localized enzyme that catalyzes the transfer of galactose to N-acetylglucosamine units 
found in glycoproteins, as well as to free lactose that is secreted in the mammary gland [166, 
167]. The in vivo biological significance of dual Ca2+ and Mn2+ sequestration within the Golgi 
of mammary gland epithelial cells remains to be tested and may extend beyond a role in 
activating intraluminal enzymes required for protein and carbohydrate modification.  
 
The evidence obtained thus far therefore indicates that PMCA2, possibly together with 
SPCAs, is a major transport mechanism for macro-Ca2+ homeostasis required for the bulk 
transfer of Ca2+ into milk during lactation. Indeed, data from lactating PMCA2-null mice 
suggests that the regulation of both PMCA and SPCA expression are somehow linked such 
that a deficiency in PMCA2 expression could be partially compensated by an increase in 
SPCA1 expression [21]. Ultimately, the development of conditional PMCA2, SPCA1 and 
SPCA2 knockout mouse models would greatly assist in determining the in vivo physiological 
roles of specific P-type Ca2+-ATPases in the mammary glands of lactating animals. 
 
1.8.2 Potential role for PMCAs in proliferation 
The regulation of cell proliferation and the cell cycle by Ca2+ and its ubiquitous sensor 
calmodulin is well recognized [60]. PMCA isoforms are involved in the regulation of rat 
vascular smooth muscle cell (VSMC) proliferation [149, 168]. Temporary elevations in 
[Ca2+]i that are associated with G1 to S phase transitions in VSMCs are partly due to a 
reduction in PMCA1 expression at the G1/S interface [149]. This effect on cell cycle related 
changes in PMCA1 expression in VSMCs is mediated by the transcription factor c-Myb, such 
that dominant interfering c-Myb constructs increase PMCA1 expression, reduce resting 
[Ca2+]i and impede G1 to S phase progression [149, 168]. The transient overexpression of 
PMCA1a has similar effects in limiting S phase entry and reducing the proliferative rate of rat 
VSMCs [149]. In a manner similar to PMCA1, PMCA4 expression is also modestly reduced 
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as mouse VSMCs progress from G1 to S phase via a mechanism involving both c-Myb and 
Ca2+/calmodulin-dependent protein kinase II [150]. Collectively, these studies suggest that c-
Myb dependent repression of PMCA1 and PMCA4 expression lowers the rate of PMCA-
driven Ca2+ efflux and thus increases [Ca2+]i, which in turn optimally triggers G1/S phase 
transitions required for proliferating VSMCs [169]. Furthermore, our laboratory has shown 
that PMCA expression is also dynamically regulated in cultured rat aortic myocytes such that 
fetal bovine serum-stimulated cells express increased levels of PMCA1 mRNA compared to 
serum-deprived cells [170].  
 
An important question that remains is whether regulation of PMCA expression or 
PMCA-mediated Ca2+ efflux, particularly of house-keeping PMCA isoforms, is specific to 
VSMCs or instead is a universal feature of cell cycle control in eukaryotic cells? In the rat 
mammary gland PMCA4 is the predominant house-keeping isoform [17]. Its protein 
expression undergoes elevation throughout pregnancy until the start of lactation when it 
sharply declines (Table 1.2) [17]. Although this elevation in PMCA4 expression is not as 
large as the increase in PMCA2 expression during lactation, this increase suggests a potential 
role for PMCA4 in mammary gland epithelial cell proliferation during pregnancy-induced 
development of secretory acini, which are the functional anatomical units of the mammary 
gland required for lactation [85, 87].  
 
1.8.3 Potential role for PMCAs in differentiation 
PMCAs are also implicated in the control of differentiation in keratinocytes [44], 
cerebellar granular neurons [143] and IMR-32 neuroblastoma cells [151]. Although 
modulation of PMCA expression or activity may not be a primary trigger driving 
differentiation, it may be a secondary event needed to support the differentiation status in 
these cell types. Inhibition of PMCA1 in PC6 pheochromocytoma cells with stable antisense 
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does, however, diminish the ability of these cells to extend neurites induced by nerve growth 
factor [43]. Similar studies looking at PMCA modulation and differentiation status in 
mammary gland epithelial cells have yet to be carried out. Considering that the mammary 
gland is a dynamic organ consisting of different cell types, any future studies investigating the 
potential roles of PMCAs in mammary gland differentiation should look at either in vivo 
models or in vitro models that also take into account the community of cells that make up the 
functional organ [171]. Overall, modulation of PMCA isoform expression in the breast may 
possibly mediate the differentiation of not just mammary gland epithelial cells but other 
mammary gland cell types such as myoepithelial cells. The differentiation of specialized cell 
types in the breast is anticipated to be under precise controls and of utmost importance, 
particularly in determining the extensive morphological and functional changes in the 
mammary gland that are induced by a full-term pregnancy and are essential for lactation. 
 
1.8.4 Potential role for PMCAs in apoptosis 
A more contentious issue concerns the role of PMCAs in the control of apoptosis. 
Indeed, the role of Ca2+ in apoptosis has been quite controversial (for reviews see [172] and 
[28]). Maintaining a low resting [Ca2+]i is necessary to support the signaling function of 
intracellular Ca2+ and to prevent cellular toxicity [2, 22]. Excessive elevation in [Ca2+]i can 
ultimately lead to apoptosis or necrosis [28, 172], however, moderate elevations in [Ca2+]i can 
be either pro-apoptotic [173, 174] or anti-apoptotic [175, 176]. The importance of PMCAs in 
the initiation or regulation of apoptosis remains ambiguous due to the lack of studies; 
however, those studies that are published provide an interesting insight. For example, 
proteolytic cleavage of PMCA4 by a major effector of apoptosis, caspase-3, in staurosporine-
treated HeLa cells generates a constitutively active PMCA4 fragment [65]. The authors 
suggest that this constitutively active PMCA4 fragment acts faster in handling rises in [Ca2+]i 
than its non-cleaved counterpart. However, whether the irreversible activation of PMCA4 by 
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caspase-3 in these cells protects against or propagates the apoptotic cascade is uncertain since 
elevations in [Ca2+]i can either precipitate cell death or form the basis of anti-apoptotic 
signals. Conversely, a similar study by Schwab et al [64] demonstrates that caspase-
dependent cleavage of PMCA4 in CHO cells stably overexpressing PMCA4 inactivates the 
pump and contributes to Ca2+ overload leading to the demise of apoptotic cells. The 
expression of non-cleavable PMCA4 mutants prevents excessive elevations in [Ca2+]i induced 
by apoptotic stimuli, delays the progression of apoptosis and also reduces the extent of 
secondary cell lysis or necrosis [64]. Furthermore, PMCA4 is required for tumor necrosis 
factor-induced apoptosis in L929 murine fibrosarcoma cells [177]. L929 cells in which 
PMCA4 is disrupted are resistant to tumor necrosis factor-induced apoptosis [177]. This 
resistance is mediated by an increase in [Ca2+]i that forms a Ca2+ signal promoting the 
exocytosis of lysosomes and thus the disruption of lysosomal function that is a key 
component of cell death [177]. Interestingly, PMCA4b physically interacts with RASSF1, a 
tumor suppressor and the complex inhibits activation of the extracellular signal-regulated 
protein kinase (ERK) pathway, suggesting that PMCA4b participates in promoting apoptosis 
by modulating this pathway [178]. An exciting finding is the regulation of PMCA activity by 
an exogenous factor. The survival factor basic fibroblast growth factor (bFGF) acts to localize 
PMCA to the plasma membrane in ovarian granulosa cells, thus regulating [Ca2+]i [179]. This 
indicates that signals that modulate cell survival may act in part through modification of Ca2+ 
efflux. Receptors for bFGF are ectopically expressed on the surface of malignant mammary 
gland epithelial cells, thus it is possible that PMCAs are involved in the survival of 
susceptible malignant breast epithelial cells [180]. Just like the possible role for PMCAs in 
mammary gland differentiation, the role of PMCA isoforms in either promoting or protecting 
against mammary gland epithelial cell apoptosis has not been assessed. The studies mentioned 
above have also focused on regulation of PMCA activity or localization during apoptosis. 
There is general uncertainty as to whether regulation of PMCA isoform expression modulates 
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apoptosis. Apoptosis is, however, a normal component of the developmental program in the 
mammary gland and is also a process involved in post-lactational involution whereby the 
cessation of suckling results in the apoptotic and phagocytic removal of secretory mammary 
gland epithelial cells [85, 87]. Any functional relationships between the regulation of PMCA 
isoform expression and mammary gland epithelial cell apoptosis may have implications for 
mammary gland pathophysiology, since resistance to apoptosis or delayed post-lactational 
involution could promote breast neoplasia [181]. 
 
1.9 When Ca2+ signaling goes wrong: implications for breast cancer 
Up till now, this review has primarily focused on the established and putative 
homeostatic functions of PMCAs in mammary gland physiology, with particular emphasis on 
the role of PMCAs in supporting the lactating phenotype. However, the duality of Ca2+ 
signaling is such that it can contribute to both physiological and pathophysiological processes 
[23, 29, 182]. We and others have proposed that deregulation of Ca2+ homeostasis in the 
mammary gland may contribute to diseases or conditions of the mammary gland [15, 38-40, 
183, 184]. Disorders of the mammary gland can range from agricultural problems such as 
milk fever, whereby the demands for Ca2+ at the onset of lactation are so extensive that it 
causes hypocalcemia in mammals such as diary cattle to breast cancer in humans [185]. 
Indeed, a connection has now been made between expression levels of Ca2+ transporters in the 
mammary gland and milk fever [186]. The remainder of this review, however, will 
concentrate on the potential causes and consequences of abnormal Ca2+ homeostasis in breast 
cancer, with a specific mention of the potential importance of PMCAs. 
 
The mechanisms underlying neoplastic initiation, promotion and progression of 
mammary gland epithelial cells in breast cancer are yet to be fully elucidated. Reproductive 
hormones such as estrogens as well as environmental carcinogens are implicated in breast 
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cancer and can act to disrupt Ca2+ homeostasis. Dimethylbenz[a]anthracene and 
benzo[a]pyrene, carcinogenic polycyclic aromatic hydrocarbons, increase [Ca2+]i in primary 
cultures of human mammary gland epithelial cells [38]. Benzo[a]pyrene also enhances the 
proliferation of human breast epithelial cells in response to epidermal growth factor (EGF) 
[38]. 17β-Estradiol as well as environmental estrogenic compounds such as bisphenol-A and 
4-tert-octylphenol cause a rapid and sustained increase in [Ca2+]i in human breast cancer cell 
lines that is not inhibited by the estrogen receptor antagonist ICI 182,780 [187]. The 
biological significance of this alteration in Ca2+ homeostasis in breast cancer development is 
uncertain. Estrogens, however, are mediators of mitogenesis in the breast [188] and thus 
sustained abnormal Ca2+ homeostasis induced by prolonged exposure to estrogenic 
compounds may contribute to uncontrolled mammary gland epithelial cell proliferation.  
 
Little is known about the potential direct involvement of aberrant Ca2+ regulation and 
signaling in breast cancer development. Studies by Gao et al suggest that a novel auxiliary 
subunit of voltage-gated Ca2+ channels, α2δ-2 (CACNA2D2), is located in a chromosomal 
region displaying either homozygous deletions or allele loss in breast as well as other cancers 
[189]. Thus, CACNA2D2 may be a tumor suppressor gene, which if lost could lead to altered 
Ca2+ homeostasis or signaling and thus contribute to breast cancer pathophysiology. It should 
be also noted that disruptions in the expression or function of Ca2+ regulators such as 
CACNA2D2 may instead be a consequence of mammary gland tumorigenesis. The potential 
role of altered Ca2+ homeostasis and signaling in contributing to the tumorigenic phenotype 
needs to be further examined and the development of appropriate in vivo models conditionally 
targeting regulators of Ca2+ homeostasis in the mammary gland will hopefully aid in this 
endeavour.  
 
 38
Disruptions in the expression of P-type Ca2+-ATPases have also been associated with 
the tumorigenic phenotype. We have previously reported that the relative expression of 
PMCA1 mRNA is greater in tumorigenic MCF-7 and MDA-MB-231 human breast cancer 
cells compared to non-tumorigenic MCF-10A human breast epithelial cells [15]. Furthermore, 
the expression of PMCA1b and PMCA4b mRNA is lower in human skin and lung fibroblasts 
neoplastically transformed by simian virus 40 (SV-40), compared to non-transformed 
counterparts [14]. The functional relevance of altered PMCA isoform expression in terms of 
the development and pathophysiology of breast and other cancers remains to be determined. 
These preliminary insights into the differential expression of PMCA isoforms between 
tumorigenic and non-tumorigenic mammary gland epithelial cells do, however, highlight the 
potential for PMCAs to be drug targets for the treatment of breast cancer. Indeed, other P-type 
ATPases such the Na+/K+-ATPase and H+/K+-ATPase are the targets of drugs commonly used 
for the treatment of heart conditions (digoxin) and acid-related gastric disorders (omeprazole), 
respectively [190]. The other alternative is that any possible differences in PMCA expression 
in certain breast cancers may be exploited such that PMCA inhibition could augment the 
sensitivity to existing anticancer agents like tamoxifen, whose therapeutic mechanism of 
action in breast cancer has partially been linked to the deregulation of Ca2+ signaling [191, 
192].  
 
Even though the study of abnormal Ca2+ homeostasis in breast cancer is in its infancy, 
there is considerable evidence that modulation of Ca2+ homeostasis and signaling represents a 
viable therapeutic approach in the treatment and/or prevention of breast cancer. Thus, other 
regulators of Ca2+ homeostasis or signaling in mammary gland tumors, not just PMCAs, are 
also probable drug targets for breast cancer. For example, pharmacological inhibition of 
Ca2+/calmodulin-dependent kinase (CaM-K) with the agent KN-93 reduces the proliferation of 
MCF-7 cells, whereas MCF-10A cells are less sensitive to the antiproliferative effects of KN-
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93 [62]. Specific targeting of CaM-KI via siRNA in MCF-7 cells leads to cell cycle arrest in 
G1 phase and cell death, suggesting this CaM-K isoform mediates the antiproliferative effect 
[62]. Inhibition of CaM-KI is therefore proposed to be a viable strategy for breast cancer 
treatment [62].  
 
Ca2+ channels are also potential drug targets in breast cancer. The relevance of 
voltage-operated Ca2+ channels in regulating cell proliferation in breast cancer cells is 
somewhat unclear with conflicting reports. Although, blockers of voltage-operated Ca2+ 
channels such as amlodipine, diltiazem and verapamil inhibit HT-39 human breast cancer cell 
proliferation and tumor growth in nude mice [193], some studies suggest that breast cancer 
cells do not express voltage-operated Ca2+ channels [193, 194]. The aforementioned Ca2+ 
channel blockers all reportedly have a variety of non-specific effects including inhibition of P-
glycoprotein [195] and reduction of voltage-dependent Na+ currents [196]. Mibefradil (T-type 
voltage-operated Ca2+ channel antagonist) inhibits T-type Ca2+ channel currents and 
proliferation in MCF-7 cells [197]. Although mibefradil may also affect other types of ion 
channels [198], future investigations into T-type voltage-operated Ca2+ channels in breast 
cancer cells appear justified given the association of this channel type with the proliferative 
phenotype in VSMCs [199] and MCF-7 cells [197].  
 
There is considerable evidence supporting the applicability of modulating the channels 
responsible for the release of Ca2+ from intracellular stores and capacitative Ca2+ entry in the 
treatment of breast cancer. Ca2+ signaling, including the release from intracellular stores such 
as the ER and influx across the plasma membrane are involved in the mitogenic effects of 
estrogens, EGF and ATP in breast cancer cells and other cell types [200-209]. Indeed, 
inhibition of capacitative Ca2+ entry and Ca2+ release from ER Ca2+ stores using SKF 96365 
and 2,5-di-tert-butyl-hydroquinone (DBHQ), respectively, reduces EGF-induced mouse 
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mammary gland epithelial cell proliferation [208]. Thus, capacitative Ca2+ entry channels are 
candidate therapeutic targets in mammary gland neoplasia. However, the molecular identities 
of the capacitative Ca2+ entry channels that have a pertinent role in breast cancer 
pathophysiology are unknown. 
 
The anti-estrogen tamoxifen, which is an established agent used in the endocrine 
treatment of breast cancer [210], has genomic and non-genomic actions [211]. Indeed, its 
cytotoxicity may in part be due to its actions on intracellular Ca2+ homeostasis [191, 192]. In 
MCF-7 cell cultures, tamoxifen enhances the expansion of Ca2+ waves that are propagated by 
the release of extracellular ATP amongst cells [192]. Tamoxifen also accelerates Ca2+ 
ionophore-induced cell death, however, this has only been confirmed in rat C6 glioma cells 
[192]. Tamoxifen induces increases in [Ca2+]i in ZR-75-1 breast cancer cells and also reduces 
cell viability, mediated by the release of Ca2+ from the ER and the subsequent induction of 
capacitative Ca2+ entry [191]. Although it may appear that stimulation of MCF-7 cell death by 
tamoxifen contradicts the aforementioned association between proliferation and enhanced 
capacitative Ca2+ entry [207], these two insights into capacitative Ca2+ entry highlight the 
dichotomous nature of Ca2+ signaling. The functional consequences of Ca2+ entry appear to be 
determined by a threshold, with cell proliferation possibly being stimulated below a threshold 
and cell death being stimulated above it. Such duality in Ca2+ signaling has been reviewed 
elsewhere [28]. The modulation of Ca2+ signals as a possible therapeutic approach in breast 
cancer would not be without its challenges. Inhibition of Ca2+ entry channels may inhibit cell 
proliferation in some breast cancers but it may also prevent the induction of cell death by 
traditional anti-neoplastic agents such as tamoxifen.  
 
Another promising approach for the treatment of breast cancer is to modulate Ca2+ 
homeostasis in order to induce apoptosis. Although the exact mechanisms are not known, 
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disturbed Ca2+ homeostasis within the lumen of the ER mediated by the anti-apoptotic protein 
Bcl-2 is linked with apoptotic resistance [28]. Bcl-2 increases Ca2+ leakage from the ER and 
reduces the amplitude of cytosolic Ca2+ oscillations induced by ATP in MCF-7 breast cancer 
cells [40]. Modulators of this Ca2+ leak may be potential drug leads, as the anti-neoplastic 
actions of epigallocatechin gallate (found in green tea) may be due to its inhibition of ER Ca2+ 
leakage mediated by Bcl-2 [40]. The active form of vitamin D, 1,25(OH)2D3, also increases 
[Ca2+]i and causes apoptosis in MCF-7 cells, by releasing Ca2+ stored within the ER and 
inducing capacitative Ca2+ entry [39, 194, 212]. Data from epidemiological studies suggest 
that higher intakes of dietary Ca2+ and vitamin D are inversely associated with breast cancer 
risk in premenopausal women [213, 214].  The roles of altered Ca2+ signaling and/or the 
expression of P-type Ca2+-ATPases and Ca2+ channels in this protection are unclear and 
require further investigation. 
 
Metastasis or invasion in advanced breast cancer, particularly to bone, is a serious 
clinical problem causing extensive morbidity and poor survival rates [215-217]. Novel targets 
are needed to develop treatments for metastatic lesions in advanced breast cancer and also for 
use as prognostic markers in identifying patients most likely to develop metastases and 
potentially benefit from early or appropriate adjuvant therapy [216, 218]. The S100 family of 
proteins is a large group of low molecular weight Ca2+-binding proteins that like calmodulin, 
possess two EF-hand structural motifs [219]. The family of S100 Ca2+-binding proteins 
consists of numerous members ranging from S100A1 to S100A13, S100B, S100C and also 
S100P [220]. S100 proteins are detectable in normal mammary gland tissue and benign breast 
samples [183, 221, 222], however, the homeostatic role of various S100 proteins in mammary 
gland physiology is virtually unknown. These Ca2+-modulated proteins may have both 
intracellular and extracellular functions to regulate diverse processes such as cytoskeleton 
structural integrity to paracrine signaling [219, 220]. Particular members of the family of 
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S100 Ca2+-binding proteins are, however, important in breast cancer progression and 
metastasis [183, 219, 220, 223-228]. Indeed S100A4, previous known as p9Ka, is a crucial 
player in breast cancer metastasis. The introduction of S100A4 into mouse mammary tumor 
virus (MMTV)-neu transgenic mice, which are already susceptible to mammary gland 
neoplasia, leads to the formation of mammary gland tumors with metastatic features [224]. 
Patient mortality is also highly correlated with detectable levels of S100A4 in breast cancer 
tissue [225]. Mechanistically, S100A4 may interact with the p53 tumor suppressor protein and 
non-muscle myosin, however, this has not been confirmed in cell-based or in vivo assays 
[227]. Functionally, the invasive properties conferred by S100A4 expression in in vitro 
models of breast cancer metastasis are due to increases in cell motility, rather than changes in 
cell proliferation, cell−substrate adhesion or the ability to degrade extracellular matrix [228]. 
Although the direct consequences of S100A4 inhibition in advanced breast cancer models 
have yet to be assessed, S100A4 in the breast represents both a potential therapeutic and 
prognostic target for metastatic breast cancer. The investigations into the effects of S100A4 
expression in breast cancer metastasis also emphasise the limitations of relying on cell 
proliferation or death assays in identifying possible drug targets for breast cancer. 
 
The Ca2+-sensing receptor (CaR) is another Ca2+-modulated protein to receive 
attention as a promising drug target for the treatment of osteolytic lesions in advanced breast 
cancer [90, 184, 229]. The CaR is a G protein-coupled receptor that is located on the surface 
of the cell, activated by Ca2+ and relays to the cell’s interior information about extracellular 
Ca2+ concentration fluctuations [66]. It is a crucial regulator of parathyroid gland physiology, 
where it monitors changes in systemic Ca2+ levels and mediates the secretion of parathyroid 
hormone (PTH), which acts to increase plasma Ca2+ to normal levels in response to 
hypocalcemia [66]. There is also evidence suggesting that the CaR is biologically significant 
in macro-Ca2+ homeostasis required for lactation [90, 184]. CaR mRNA expression in the 
 43
mammary glands of mice increases gradually as pregnancy progresses, is elevated during 
lactation and then sharply falls with post-lactational involution [90]. The use of an in vitro 
model whereby primary mouse mammary gland epithelial cells were induced to form 
mammospheres, shows that CaR is localized to the basolateral surface of luminal epithelial 
cells [90]. Stimulation of the CaR via a calcimimetic agonist increases transcellular Ca2+ 
transport, observed as an increase in the accumulation of Ca2+ within the lumen of 
mammospheres and also leads to increased milk Ca2+ content, in mice fed with a low-Ca2+ 
diet [90]. The CaR also regulates the production of parathyroid hormone-related protein 
(PTHrP) by mammary gland epithelial cells [90]. PTHrP is very similar to PTH in its actions 
and as well as having possible paracrine signaling roles, it is detectable in the systemic 
circulation during pregnancy and lactation and thus can facilitate the increased demands for 
Ca2+ during this period [230]. Elevated PTHrP expression is an important mediator of bone 
degradation caused by breast cancer metastases [215, 216]. Furthermore, the interactions 
between metastatic breast cancer cells and osteoclasts is believed to initiate a cascade of 
events that ultimately leads to bone destruction and exposes tumor cells to elevated 
extracellular Ca2+ concentrations within the local bone microenvironment [216]. Increasing 
concentrations of extracellular Ca2+ stimulates the secretion of PTHrP in MCF-7 and MDA-
MB-231 human breast cancer cells, which express the CaR [229]. Although this effect on 
PTHrP secretion in MCF-7 and MDA-MB-231 was not evaluated directly, the CaR appears to 
be the likely mediator of PTHrP secretion stimulated by extracellular Ca2+ in osteolytic breast 
cancer metastases [90]. Thus, although the primary role of the CaR in the normal breast 
appears to be in regulating PTHrP secretion by the mammary gland to maintain systemic Ca2+ 
homeostasis during the demands of lactation as part of a negative feedback loop, CaR 
expression by metastatic breast cancer cells may do the reverse in the bone microenvironment 
to establish instead a positive feedback loop [184, 229]. A scenario could exist where elevated 
extracellular Ca2+ levels within osteolytic metastases stimulates CaR-mediated PTHrP 
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secretion by metastatic breast cancer cells, which in turn stimulates bone resorption induced 
by PTHrP and the further release of Ca2+ into the extracellular environment. Whether CaR 
expression in breast cancer cells is an inherent attribute of tumorigenic cells with the 
propensity to metastasize or an acquired property of metastasized cells due to exposure to the 
bone microenvironment is unknown. Although CaR expression in breast cancer as a 
biomarker may have limitations in terms of prognostic value, it may be a drug target for 
advanced breast cancer since there is currently a lack of specific therapies that address the 
primary mediators of osteolytic metastases in breast cancer. 
 
1.10 Conclusion 
It is apparent from this review that Ca2+ homeostasis in the mammary gland is not only 
vital for milk Ca2+ concentration during lactation but is also potentially highly significant in 
other cellular processes that are influential in mammary gland development and post-
lactational involution (Fig. 1.4A). PMCAs along with other P-type Ca2+-ATPases are 
implicated to varying degrees, in regulating proliferation, differentiation and apoptosis in the 
breast. There is reasonable evidence to support that PMCA2 in the lactating mammary gland 
is a major mediator of milk Ca2+ enrichment by directly transporting ionized Ca2+ into the 
alveolar lumen. This is in contrast to the previously held view that the secretion of Ca2+ 
complexed with caseins is the primary means of Ca2+ transfer into milk. The role of other 
PMCA isoforms in regulating the proliferation, differentiation and apoptosis of mammary 
gland epithelial cells has yet to be directly assessed and may influence normal breast 
development and post-lactational involution in the in vivo situation. Disturbances in these 
basic cellular processes are likely to have important consequences for mammary gland 
tumorigenesis, since cancers generally exhibit characteristics of excessive proliferation, 
dedifferentiation and resistant apoptosis [152, 153]. The homeostatic functions of other P-type 
Ca2+-ATPases such as SPCAs in the mammary gland are at present uncertain but given the 
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importance of intracellular organelle Ca2+ accumulation in protein synthesis and processing, 
these primary active Ca2+ transporters are also likely to be crucial regulators of milk protein 
secretion.  
 
Deregulation of Ca2+ homeostasis and signaling is postulated to contribute to the 
development of and/or have important consequences in terms of mammary gland 
pathophysiology, primarily in the form of breast caner (Fig. 1.4B). A causative role for Ca2+ 
deregulation in mammary gland tumorigenesis is currently doubtful. Alterations in PMCA 
expression have been implicated in other diseases of abnormal proliferation such as 
hypertension. Modulation of Ca2+ homeostasis or signaling may regulate cell proliferation, 
differentiation and apoptosis in breast cancer. P-type Ca2+-ATPases along with other 
regulators and sensors of Ca2+ signaling therefore represent often overlooked but potential 
targets for the development of therapeutic, preventative and prognostic approaches in the 
management of breast cancer. Thus, key questions remain, not only in regards to how Ca2+ is 
transported into milk but also in relation to the biological significance of Ca2+ signaling in 
mammary gland development, post-lactational involution and pathophysiology, as well as the 
suitability of P-type Ca2+-ATPases like PMCAs as drug targets in the breast. 
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Figure 1.4. The known and potential roles of PMCAs in the mammary gland. A) A combined 
view of what is known and speculated in the case of mammary gland physiology. B) A 
combined view of what is known and speculated in the case of mammary gland 
pathophysiology, manifiested here as breast cancer. 
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1.11 Hypotheses and aims 
Hypotheses 
• Regulation of PMCA isoform expression is disrupted in breast cancer 
• Inhibition of PMCA expression in an in vitro model of breast cancer has important 
effects in modulating intracellular Ca2+ homeostasis, cell proliferation, differentiation 
and apoptosis 
 
Aims 
• To compare the levels of PMCA isoform mRNA expression between tumorigenic 
human breast cancer cell lines and non-tumorigenic human mammary gland epithelial 
cell lines 
• To establish an in vitro breast cancer model where PMCA expression can be stably 
inhibited and to characterize the consequences of PMCA inhibition in relation to 
intracellular Ca2+ homeostasis, cell proliferation, differentiation and apoptosis 
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CHAPTER TWO 
PMCA ISOFORM EXPRESSION IN HUMAN BREAST 
CANCER CELL LINES 
 
2.1 Foreword 
It is well established that PMCA isoforms are differentially expressed in different 
tissues and specialized cell types, suggesting that the expression of particular PMCA isoforms 
is matched to suit distinct physiological roles [98, 99, 107, 108]. As summarized by section 
1.7 of the literature review forming chapter one, it is also apparent that dynamic regulation of 
PMCA expression is an important homeostatic mechanism that allows cells to adapt their Ca2+ 
transport or signaling requirements to changes in physiological situations or stimuli. Dynamic 
changes in PMCA expression that occur in the rat mammary gland during the transition from 
pregnancy to lactation are likely to be highly influential in contributing to milk Ca2+ 
concentration (macro-Ca2+ homeostasis) [16, 17, 21]. Section 1.8 of chapter one also outlines 
that dynamic modulation of PMCA isoform expression may possibly mediate proliferation, 
differentiation and apoptosis in the mammary gland, which in turn are likely to affect normal 
physiological phenomena such as mammary gland development and post-lactational 
involution. Disrupted regulation of PMCA isoform expression in the mammary gland may 
therefore have pathophysiological consequences, which in humans could have implications 
for breast cancer. Indeed, some breast cancers appear to express unique sets of PMCA 
isoforms and PMCA1 mRNA expression is elevated in tumorigenic MCF-7 and MDA-MB-
231 breast cancer cells when contrasted with non-tumorigenic MCF-10A breast epithelial 
cells [15]. Thus, it is postulated that regulation of PMCA gene expression is abnormal in 
pathophysiological states of the mammary gland and PMCA isoforms are aberrantly 
expressed in breast cancer. To evaluate the plausibility of this supposition, chapter two of this 
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thesis compares PMCA isoform mRNA expression between tumorigenic human breast cancer 
and non-tumorigenic human breast epithelial cell lines.  
 
The following chapter explores if particular PMCA isoforms are aberrantly expressed 
in some breast cancer cell lines and is composed of a paper that is published in Biochemical 
and Biophysical Research Communications and has been inserted here in slightly altered 
format to fit with the style of this thesis [231]. This publication is then followed by 
supplementary material, which has not been previously published elsewhere.  
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2.2.1 Abstract 
There is evidence to suggest that PMCA isoforms are important mediators of 
mammary gland physiology. PMCA2 in particular is upregulated extensively during lactation. 
Expression of other isoforms such as PMCA4 may influence mammary gland epithelial cell 
proliferation and aberrant regulation of PMCA isoform expression may lead or contribute to 
mammary gland pathophysiology in the form of breast cancers. To explore whether PMCA2 
and PMCA4 expression may be deregulated in breast cancer, we compared mRNA expression 
of these PMCA isoforms in tumorigenic and non-tumorigenic human breast epithelial cell 
lines using real time RT-PCR. PMCA2 mRNA has a higher level of expression in some breast 
cancer cell lines and is overexpressed more than 100-fold in ZR-75-1 cells, compared to non-
tumorigenic 184B5 cells. Although differences in PMCA4 mRNA levels were observed 
between breast cell lines, they were not of the magnitude observed for PMCA2. We conclude 
that PMCA2 mRNA can be highly overexpressed in some breast cancer cells. The 
significance of PMCA2 overexpression on tumorigenicity and its possible correlation with 
other properties such as invasiveness requires further study. 
 
Keywords 
Calcium, PMCA, mammary gland, lactation, breast cancer, mRNA, transcription 
 
 52
2.2.2 Introduction 
Free intracellular calcium (Ca2+) controls many essential cellular processes. The 
fidelity of Ca2+ signaling depends on homeostatic mechanisms that maintain steep Ca2+ 
gradients across biological membranes [1, 2, 22]. Mechanisms that lower the intracellular 
Ca2+ concentration ([Ca2+]i) prevent excessive rises in [Ca2+]i and thus circumvent cellular 
toxicity [1, 2, 22]. Plasma membrane Ca2+-ATPases (PMCAs) represent one such mechanism 
and belong to a family of P-type Ca2+-ATPases that specifically and actively transport Ca2+ 
[7]. PMCAs are important modulators of intracellular Ca2+ signals as they can affect the 
dynamics of Ca2+ signals by modulating amplitude and duration [114, 120].  
 
PMCA isoforms (PMCA1−4) are encoded by genes located on separate chromosomes 
[7]. PMCA1 and PMCA4 are expressed ubiquitously while PMCA2 and PMCA3 are 
generally found in excitable tissues [99]. PMCAs differ in their biochemical properties, with 
PMCA2 having the greatest affinity for calmodulin, which is the main activator of PMCA-
mediated Ca2+ transport [111, 112]. The distinct features of PMCAs suggest that the 
expression of different PMCA isoforms is matched to suit the requirements for maintaining 
Ca2+ homeostasis in particular cell types or tissues and thus support the cell or tissue’s cellular 
and physiological functions [97]. 
 
The mammary gland experiences extensive Ca2+ flux during lactation [18, 19], yet our 
understanding of the relative importance of PMCAs in milk production and their potential 
involvement in other key processes in mammary gland physiology is limited. Rat mammary 
gland expresses PMCA1, 2 and 4 [16, 17]. PMCA2 expression undergoes significant 
induction after parturition, then rapidly increases as lactation progresses and remains elevated 
at levels that are almost 100-fold higher compared to levels during pregnancy [16, 17]. 
Moreover, null mutations in PMCA2 substantially lower milk Ca2+ concentrations in lactating 
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mice [21]. Thus, there is strong evidence supporting PMCA2 as a major mechanism for the 
enrichment of Ca2+ into milk and thus extracellular Ca2+ homeostasis. Dynamic and co-
ordinated regulation of PMCA isoform expression appears to be a crucial regulatory 
mechanism for supporting the unique physiology of the mammary gland [16, 17].  
 
Other PMCA isoforms may also control breast development, architecture and post-
lactational involution in humans, since particular PMCA isoforms mediate proliferation, 
differentiation and apoptosis in other cell culture model systems [43, 65, 149]. Little is known 
about exactly how PMCA isoforms are regulated in the mammary gland to meet different 
physiological circumstances, for example formation of glandular structures versus secretory 
acini. Deregulation of co-ordinated and dynamic PMCA isoform expression in the mammary 
gland is hypothesized to contribute to pathological consequences such as mammary gland 
tumorigenesis. We previously reported that the relative expression of PMCA1 mRNA is 
significantly higher in tumorigenic MCF-7 and MDA-MB-231 human breast cancer cell lines, 
compared to non-tumorigenic MCF-10A human breast epithelial cells [15]. We have also 
shown that expression of stable antisense targeting PMCA inhibits the proliferation of MCF-7 
cells [232]. To further explore the plausibility that deregulation of PMCA isoform expression 
is characteristic of mammary gland tumorigenesis and given that transcriptional modulation 
represents the most likely means for PMCA regulation in the course of changing 
physiological demands [143, 144, 233], we compared levels of PMCA2 and PMCA4 mRNA 
in a bank of tumorigenic and non-tumorigenic human breast epithelial cell lines. 
 
2.2.3 Materials and Methods 
2.2.3.1 Cell Culture 
The tumorigenic human breast cancer cell lines MCF-7 and MDA-MB-231 and the 
non-tumorigenic human breast epithelial cell line MCF-10A were cultured and plated for total 
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RNA isolations as previously described [15]. The tumorigenic human breast cancer cell lines 
ZR-75-1, T-47D, BT-483 and SK-BR-3 and the non-tumorigenic human breast epithelial cell 
lines 184A1 and 184B5 were a generous gift from Professor Rob Sutherland (Garvan 
Institute, Sydney, Australia). The aforementioned tumorigenic cell lines were grown in basal 
DMEM containing phenol red (JRH Biosciences, Brooklyn, Victoria, Australia) and 
supplemented with 10 % FBS (JRH Biosciences), 2 mM L-glutamine (Invitrogen, Mount 
Waverly, Victoria, Australia) and 100 U/ml−100 µg/ml penicillin G−streptomycin 
(Invitrogen). 184A1 and 184B5 cells were cultured in phenol red containing basal MCDB 170 
medium (Invitrogen), with the inclusion of 100 U/ml−100 µg/ml penicillin G−streptomycin 
and serum-free supplements provided by the manufacturer that were used at the recommended 
dilution (Invitrogen). ZR-75-1, T-47D, BT-483, SK-BR-3, 184A1 and 184B5 cells were 
routinely passaged once a week or when approximately 90 % confluent and subcultured into 
T-75 cm2 or T-150 cm2 cell culture flasks (in the case of the non-tumorigenic cells) at a split 
ratio of 1:5−1:10. Cultures were harvested for isolation of total RNA when they reached 
confluence. All cell lines were maintained in a humidified 5 % CO2/95 % air incubator at 37° 
C.  
 
2.2.3.2 RNA Isolation 
Total RNA was isolated using RNeasy mini or midi columns (Qiagen, Doncaster, 
Victoria, Australia) according to the manufacturer’s instructions. This procedure included an 
on-column DNA digestion step using RNase-free DNase I (Qiagen). Total RNA 
concentrations were quantified by measuring UV absorbance at 260 nm.  
 
2.2.3.3 Real time RT-PCR 
TaqMan real time RT-PCR assays were used to determine the expression of PMCA2 
and PMCA4 mRNA, relative to the 18S rRNA. For the relative quantification of PMCA2 
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mRNA (GenBank accession no. NM_001683) primers and probe were designed using Primer 
Express software, version 1.5 (Applied Biosystems, Scoresby, Victoria, Australia). The 
primers had the following sequences: forward primer 5’-ATCACCCGGCAGCCTCTT-3’ and 
reverse primer 5’-TTGGAGTAAAAGTCGCTGTTGGT-3’ and probe sequence was: 5’-
CCGAGCAAGGACCG-3’. The TaqMan Gene Expression Assay Hs00608066_m1 (Applied 
Biosystems) was used to quantitate PMCA4 mRNA and primers and probe for 18S rRNA 
(part number: 4308329) were also purchased from Applied Biosystems. 
 
For all reactions quantitating 18S rRNA, primers and probe were included at 50 nM 
and were cycled in separate tubes at a 1:1000 dilution of total RNA using the same method as 
for each specific target. PMCA2 mRNA was quantitated using a one-step RT-PCR procedure 
and the TaqMan one-step RT-PCR master mix reagents kit (Applied Biosystems), primers 
(900 nM), probe (200nM) and total RNA (100 ng for PMCA2, 0.1 ng for 18S rRNA). 
Reactions were cycled using an ABI PRISM 7700 Sequence Detector (Applied Biosystems) 
with the following thermal cycling conditions: 48° C for 30 min, 95° C for 10 min, followed 
by 40 cycles at 95° C for 15 s and 60° C for 1 min.  
 
First strand cDNA synthesis required for real time PCR detection of the PMCA4 
amplicon was prepared using the Omniscript RT kit according to the vendor’s instructions 
(Qiagen). Real time PCR amplifications for PMCA4 mRNA and 18S rRNA amplicons were 
then set up as separate reactions in TaqMan universal PCR master mix (Applied Biosystems). 
Each tube for real time PCR detection of PMCA4 mRNA contained cDNA template 
equivalent to 25 ng of total RNA and for 18S rRNA 0.025 ng total RNA. Thermal cycling 
was completed using an Applied Biosystems 7500 Real Time PCR System with 95° C for 10 
min and then 40 cycles at 95° C for 15 s and 60° C for 1 min.  
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2.2.3.4 Data and Statistical Analysis 
Analysis of PMCA2 mRNA real time RT-PCR data were carried out using the 
comparative CT method [15, 170, 234]. PMCA4 mRNA real time RT-PCR data were 
analyzed using the relative standard curve method. See User Bulletin #2: ABI PRISM 7700 
Sequence Detection System December 11, 1997 (updated 10/2001) from Applied Biosystems 
for further information. Data points represent the mean ± the standard error of the mean 
(SEM). N values are given in the figure legends for each corresponding graph. Means were 
compared with one-way analysis of variance (ANOVA) and subsequent Tukey’s pair-wise 
comparison tests using Prism Version 4.03 (GraphPad Software, San Diego, CA). Differences 
were considered to be statistically significant if P values were less than 0.05 (P < 0.05).  
 
2.2.4 Results and Discussion 
2.2.4.1 PMCA2 and PMCA4 mRNA Expression in MCF-7, MDA-MB-231 and MCF-10A 
Cells 
Breast cancer cell lines express multiple PMCA mRNA isoforms and our laboratory 
has previously observed that relative PMCA1 mRNA expression is greater in tumorigenic 
MCF-7 and MDA-MB-231 cells compared to non-tumorigenic MCF-10A cells [15]. To see if 
there are also differences in the expression of other PMCA mRNA isoforms in the above cell 
lines, we performed real time RT-PCR for PMCA2 and PMCA4 mRNA. Fig. 2.1 shows the 
results for relative PMCA2 mRNA expression in subconfluent and confluent cultures of 
MCF-7, MDA-MB-231 and MCF-10A cells. 
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Figure 2.1. Relative PMCA2 mRNA levels in MCF-7, MDA-MB-231 and MCF-10A cells, 
normalized to confluent MCF-10A cells and expressed as -∆∆CT values. Bars represent the 
mean ± SEM (n = 4, 4, 3, 3, 4 and 4 for samples left to right). The asterisk (*) denotes a 
significant difference compared to confluent MCF-10A cells using a Tukey’s test.  
 
Relative PMCA2 mRNA levels within a cell line did not differ significantly with the state of 
confluence. PMCA2 mRNA expression was, however, significantly greater in the confluent 
breast cancer cell lines MCF-7 and MDA-MB-231 compared to confluent normal breast 
MCF-10A cells (Fig. 2.1). In contrast, relative PMCA4 mRNA expression in subconfluent 
and confluent MCF-7, MDA-MB-231 and MCF-10A cells showed no significant differences 
either within or between cell lines (Fig. 2.2). 
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Figure 2.2. Relative PMCA4 mRNA levels in MCF-7, MDA-MB-231 and MCF-10A cells, 
normalized to confluent MCF-10A cells and expressed as fold change. Bars represent the 
mean ± SEM (n = 4 for all samples). No significant differences were found between all pair-
wise comparisons using Tukey’s tests. 
 
2.2.4.2 PMCA2 and PMCA4 mRNA Expression in Other Breast Epithelial Cell Lines 
We then assessed relative PMCA2 and PMCA4 mRNA levels in a larger array of 
tumorigenic ZR-75-1, T-47D, BT-483 and SK-BR-3 cells and two other non-tumorigenic 
184A1 and 184B5 cell lines. Non-tumorigenic 184A1 and 184B5 cells did not differ 
significantly from each other in their relative expression of PMCA2 mRNA (Fig. 2.3).  
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Figure 2.3. Relative PMCA2 mRNA levels in an extended panel of tumorigenic (ZR-75-1, T-
47D, BT-483 and SK-BR-3) and non-tumorigenic (184A1 and 184B5) breast epithelial cell 
lines. Bars represent the mean ± SEM (n = 3 for all samples) and are indicative of two 
independent experiments. The asterisk (*) denotes a significant difference compared to 184B5 
cells using a Tukey’s test. 
 
Except for SK-BR-3 cells, relative PMCA2 mRNA expression was significantly higher in all 
the tumorigenic cell lines tested, when compared to 184B5 cells (Fig. 2.3). Different levels of 
PMCA2 mRNA expression were observed within the group of tumorigenic cell lines 
examined, with ZR-75-1 cells expressing the highest level of PMCA2 mRNA. The ZR-75-1 
breast cancer cells express a more than 100-fold greater level of PMCA2 mRNA compared to 
the normal 184B5 cell line (fold change = TC∆∆−2 ). 
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Whereas house-keeping PMCA isoforms such as PMCA4 may predominately 
influence processes like pregnancy-induced mammary gland development or cell proliferation 
in the breast [17, 232], the evidence for PMCA2 in the mammary gland suggests that PMCA2 
is primarily a mechanism for bulk Ca2+ transport during lactation for the enrichment of milk 
with Ca2+ [16, 17, 21]. Since lactation is protective against breast cancer in premenopausal 
women [235], the finding that PMCA2 is overexpressed in tumorigenic cell lines (Fig. 2.1 and 
Fig. 2.3) as well as being present in ZR-75-1 at levels 100-fold greater than the non-
tumorigenic cell lines is intriguing and suggests that some breast cancers may be 
characterized by the overexpression of Ca2+ transporters associated with lactation. Indeed, 
STAT5a is a protein involved in mammary gland development and milk protein expression 
during lactation [236, 237] that may also be involved in breast cancer [238, 239]. Our studies 
indicate that the increased levels of PMCA2 in some breast cancer cell lines is not correlated 
with estrogen receptor status, since the estrogen receptor negative cell line MDA-MB-231 had 
elevated levels of PMCA2. 
 
PMCA4 mRNA expression in all the cell lines examined varied modestly with a 
narrower dynamic range than that seen for PMCA2 mRNA. Indeed, the greatest difference 
between two breast cell lines for PMCA4 was approximately 8-fold, whereas for PMCA2 it 
was more than 100-fold. However, there was a modest but significantly lower level of 
PMCA4 mRNA in the tumorigenic samples when compared to the 184B5 non-tumorigenic 
cell line (Fig. 2.4).  
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Figure 2.4. Relative PMCA4 mRNA levels in an extended panel of tumorigenic (ZR-75-1, T-
47D, BT-483 and SK-BR-3) and non-tumorigenic (184A1 and 184B5) breast epithelial cell 
lines. Bars represent the mean ± SEM (n = 3 for all samples) and are indicative of two 
independent experiments. The asterisk (*) denotes a significant difference compared to 184B5 
cells using a Tukey’s test. 
 
The differences in PMCA4 mRNA levels seen in this study could be of functional importance 
given that a reduction in PMCA4 expression is correlated with an inhibition of MCF-7 breast 
cancer cell line proliferation [232] and may suggest a slightly greater sensitivity to selective 
PMCA4 inhibition in tumorigenic cell lines. However, the modest differences between cell 
lines in PMCA4 may reflect a more house-keeping role for PMCA4 compared with PMCA2, 
which has a highly restricted tissue distribution [99] and is the PMCA isoform with the 
greatest change in expression associated with lactation [16, 17]. 
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The potential biological significance of PMCA2 overexpression in breast 
tumorigenesis as well as its impact on Ca2+ signaling in mammary gland epithelial cells is 
uncertain. Our study does further highlight the isoform specific differences in PMCA 
expression in epithelial cells of the mammary gland. Future studies are required to determine 
if relative levels of PMCA isoforms correlate to clinical outcomes or sensitivity to specific 
treatment regimes. Further studies are also required to examine the mechanisms of PMCA 
isoform transcriptional and translational regulation particularly in mammary gland epithelial 
cells during lactation and breast cancer. 
 
2.2.5 Acknowledgements 
We would like to Dr Jodie Robinson and Nicola Holman for assistance with 
methodology.  
 
2.3 Supplementary Material 
This next section presents data that were not included in the paper presented above 
[231]. It also discusses potential reasons for how and why PMCA2 is overexpressed in some 
breast cancer cell lines and considers the implications of this finding for breast cancer 
progression and therapeutics. This unexpected result is of particular interest as PMCA2 
expression is highly elevated in the lactating rat mammary gland. It will hopefully encourage 
further research into the regulatory mechanisms that are responsible for PMCA isoform 
expression in mammary gland physiology and pathophysiology.  
 
2.3.1 Introduction 
One of the characteristic features of ZR-75-1 cells is that they are a breast cancer cell 
line exhibiting pronounced overexpression of the tumor antigen mucin 1 (MUC1), which 
initiates down-stream effects via Ca2+ signals [240, 241]. MUC1 expression in the mammary 
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gland like PMCA2 is also modulated by pregnancy and lactation [242]. Therefore, to explore 
a possible mechanistic basis for the considerable elevation of PMCA2 mRNA that was 
observed in ZR-75-1 cells, PMCA2 and MUC1 mRNA expression in several clones of MDA-
MB-453 breast cancer cells stably transfected with either a MUC1-encoding vector or an 
empty control vector was examined.  
 
2.3.2 Materials and Methods 
2.3.2.1 Cell Culture 
MDA-MB-453 human breast cancer cells (American Type Culture Collection) were 
stably transfected either with a MUC1 cDNA encoding the transmembrane isoform of MUC1 
with 22 tandem repeats in the pcDNA3 vector or the empty vector alone as a control. These 
cell lines were provided by Assoc Prof Mike McGuckin (Mater Medical Research Institute, 
Brisbane, Australia). Stable clones were isolated after selection in 400 µg/mL G418 
(Promega, Annandale, NSW, Australia) and MUC1 expression determined by flow cytometry 
with the BC2 antibody [240]. One control vector transfected clone (C13) and three MUC1-
expressing clones (M24, M41 and M48) were used for experiments. These clones were grown 
in phenol red containing RPMI 1640 medium (Invitrogen) with 10 % FBS, 2 mM L-
glutamine and 200 µg/ml G418. Confluent cultures of MDA-MB-453 clones in 10 cm 
diameter dishes were harvested for RNA isolation using RNeasy midi columns (Qiagen). The 
above cell lines were maintained in a humidified 5 % CO2/95 % air incubator at 37° C.  
 
2.3.2.2 Real time RT-PCR 
Relative expression of MUC1 mRNA levels were assessed in the stably transfected 
MDA-MB-453 clones using a pre-developed TaqMan Gene Expression Assay from Applied 
Biosystems (assay ID: Hs00410317_m1) and the relative standard curve method of analysis. 
The Omniscript RT kit (Qiagen) was used for first strand cDNA synthesis. Converted cDNA 
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equivalent to 30 ng of total RNA was used in each MUC1 amplification reaction, whereas 
reactions for 18S rRNA contained cDNA equal to 0.3 ng of total RNA. 18S rRNA 
amplification reactions were similarly performed using a TaqMan Gene Expression Assay 
from Applied Biosystems (part number: 4319413E). Separate real time PCR amplifications 
for MUC1 mRNA and 18S rRNA amplicons were set up in TaqMan universal PCR master 
mix (Applied Biosystems). Thermal cycling conditions for relative quantification of MUC1 
mRNA consisted of 95° C for 10 min, followed by 40 cycles at 95° C for 15 s and 60° C for 1 
min and were performed on an Applied Biosystems 7500 real time PCR system. Assessment 
of relative PMCA2 mRNA levels was carried out as described in the paper above, in sections 
2.2.3.3 and 2.2.3.4 of this chapter. 
 
2.3.3 Results and Discussion 
The results comparing PMCA2 and MUC1 mRNA expression between MDA-MB-
453 cells stably transfected with either a MUC1 encoding vector or an empty control vector 
are shown in Fig. 2.5. 
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Figure 2.5. Relative expression of PMCA2 mRNA versus MUC1 mRNA in MDA-MB-453 
clones with either an empty control vector (clone C13) or a MUC1-encoding vector (clones 
M24, M41 and M48). Points represent the mean expression levels for both PMCA2 and 
MUC1 mRNA ± SEM (n = 6 for all samples). The equation to the line of best fit as 
determined by linear regression and the r-squared value is provided in the graph. 
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There appeared to be no clear correlation between PMCA2 and MUC1 mRNA expression in 
the MDA-MB-453 cell line, thus suggesting that MUC1 levels do not directly regulate the 
expression of PMCA2 (Fig. 2.5). Although MUC1 does not directly regulate the expression of 
PMCA2 (Fig. 2.5), these two genes may share a common transcriptional regulator. 
Alternatively, the expression of PMCA2 and MUC1 in the mammary gland is perhaps 
modulated by the same hormone or hormonal cues. Indeed, potential modulation of PMCA 
expression in the mammary gland by many reproductive hormones such as progesterone and 
prolactin, which are known to mediate differentiation in the breast, remains to be tested [243]. 
Further studies of the PMCA2 promoter region, as has been previously carried out for MUC1, 
may reveal this relationship [244]. 
 
As detailed in section 2.2.4 of this chapter, PMCA2 is overexpressed in some breast 
cancer cell lines, most notably ZR-75-1. Similarly, studies by Reinhardt and colleagues show 
that PMCA2 is upregulated in the lactating rat mammary gland [16, 17]. MUC1 is a tumor 
surface antigen that is overexpressed not only in ZR-75-1 cells but also in other breast cancer 
cells, although not to the same extent [240]. The expression of MUC1 in the mammary gland 
also appears to be developmentally regulated such that its levels are elevated during mid-
pregnancy and lactation [242]. It is therefore possible that increased expression of both 
PMCA2 and MUC1 in ZR-75-1 cells, rather than being a direct relationship, is a consequence 
related to the differentiation status of these cells such that some breast cancers adopt features 
of the lactating phenotype or retain similar characteristics if mammary gland tumors arise due 
to deficiencies in post-lactation involution [181]. This concept may at first seem perplexing, 
especially when lactation is protective against breast cancer in premenopausal women [235]. 
However, other proteins such as the signal transducers and activators of transcription (STAT), 
which are important lactogenic mediators, are also implicated in breast cancer [238, 239]. The 
secretion of parathyroid hormone-related protein (PTHrP) by the mammary gland and its 
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regulation by the Ca2+-sensing receptor (CaR) to facilitate the increased demand for milk Ca2+ 
enrichment and maintain systemic Ca2+ homeostasis is another defining characteristic of 
lactation, yet CaR-mediated secretion of this hormone by breast cancer cells is also likely to 
be an important mechanism involved in breast cancer metastases to bone [90, 229]. The other 
possibility that should not be discounted and may contribute to the overexpression of PMCA2 
in certain cell lines is that PMCA isoform expression may be subjected to differential 
regulation depending on whether a mammary gland epithelial cell resembles a luminal or 
basal, otherwise known as myoepithelial, cell type [245, 246]. PMCA2 upregulation by some 
breast cancers may be of prognostic value in the clinic and future studies correlating PMCA2 
expression with markers of malignancy in breast cancer tumor samples or patient survival 
would be of special interest. As yet, the functional relevance of PMCA2 overexpression in 
some tumorigenic breast epithelial cell lines, as well as the expression of other PMCA 
isoforms, in relation to mammary gland pathophysiology remains uncertain. Therefore, to 
evaluate if PMCA expression in the mammary gland may play a role in fundamental cellular 
processes that are disturbed in breast cancer, the second aim of this thesis was to characterize 
the consequences of PMCA inhibition in terms intracellular Ca2+ homeostasis, cell 
proliferation, differentiation and apoptosis. The next chapter details the effects of PMCA 
inhibition in MCF-7 human breast cancer cells with the use of a tetracycline-regulated stable 
antisense approach. 
 
2.3.4 Acknowledgement 
I would like to thank Associate Professor Michael McGuckin (Mater Medical 
Research Institute, Brisbane, Australia) for offering helpful comments and for providing the 
MDA-MB-453 control vector and MUC1-expressing clones.  
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CHAPTER THREE 
CONSEQUENCES OF PMCA INHIBITION IN MCF-7 
HUMAN BREAST CANCER CELLS 
 
3.1 Foreword 
Chapter two demonstrated the possibility that some PMCA isoforms, for example 
PMCA2, are abnormally overexpressed in some breast cancers. Studies by Reinhardt and co-
workers also show that upregulation of PMCA2 in the mammary gland during lactation is a 
highly plausible mechanism of milk Ca2+ concentration [16, 17, 21]. There is therefore 
emerging evidence that modulation of PMCA expression is an important mediator of bulk 
Ca2+ homeostasis, which contributes to physiological processes such as lactation in the normal 
mammary gland. However, as explored in the literature review presented in chapter one, little 
is known about the biological significance of mammary gland PMCA expression in 
controlling other cellular processes like proliferation, differentiation and apoptosis, which are 
regulated by intracellular Ca2+ signals but are deregulated in pathophysiological states such as 
breast cancer. Thus, the functional consequences of inhibiting mammary gland PMCA 
expression and its relevance for breast cancer are unknown. The aim of chapter three is to 
evaluate whether inhibition of PMCA expression in the commonly employed MCF-7 human 
breast cancer cell line has important effects in influencing intracellular Ca2+ homeostasis, cell 
proliferation, differentiation and apoptosis. 
 
To achieve the above aim in characterizing the consequences of PMCA inhibition in 
MCF-7 cells, a molecular approach was employed. This was required because presently 
available inhibitors of PMCAs are non-specific in that they inhibit other P-type ATPases or 
Ca2+ efflux pathways [7, 247, 248]. Caloxin 1A1 for instance, is a synthetic peptide inhibitor 
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of PMCAs that also has been reported to inhibit SERCAs [249]. Cyclosporine A, which is 
also a peptide drug commonly used for immunosuppression inhibits PMCA activity, however, 
it is well documented that this agent modulates other components involved in the transduction 
of Ca2+-mediated signaling pathways, for example the Ca2+-sensitive phosphatase calcineurin 
and its transcription factor target, NF-AT [125, 250]. The current availability of 
pharmacological agents to inhibit PMCA activity is therefore hampered due the lack of target 
specificity and the possibility that they may influence Ca2+ signaling pathways by alternate 
means. It is due to this methodological dilemma that a stable and conditional antisense 
approach was used to attempt knockdown of PMCA expression, rather than pharmacological 
inhibition of PMCA activity. The term antisense generally describes a nucleotide sequence 
that hybridizes with and is the reverse-complement of a particular mRNA sequence, therefore 
possibly leading to disruption of target mRNA splicing, mRNA degradation or inhibition of 
mRNA translation into protein [251]. Although antisense technology is now largely 
superseded by more effective and efficient alternatives such as RNA interference (RNAi), the 
application of RNAi in mammalian systems with small interfering RNA (siRNA) was still in 
its infancy when the aim of this chapter was first pursued [252-254]. Nevertheless, both 
technologies have demonstrated capacity to successfully achieve their ultimate objective, 
which is to knockdown gene expression so that the functional consequences of target protein 
inhibition can be characterized [43, 255-258].  
 
The decision to use a stable, as opposed to transient antisense technique, as a method 
of PMCA inhibition was dictated by the knowledge that the PMCA is reported to have a 
relatively long protein half-life of approximately 12 days [154]. Therefore, stable expression 
of an antisense transcript in an engineered cell line, which facilitates long-term inhibition of 
target protein expression, would be particularly suited to characterizing the effects of PMCA 
protein inhibition with antisense technology [259]. This chapter encompasses the generation 
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and utilization in subsequent experiments of a stable MCF-7 Tet-off human breast cancer cell 
line that was designed to conditionally express PMCA antisense. The Tet-off gene expression 
system is derived from a similar system that regulates inducible resistance to tetracycline 
antibiotics in prokaryotes [260]. The presence or absence of tetracycline in the culture 
medium regulates gene expression from this system. When tetracycline or its analogue 
doxycycline is present, gene expression is turned off; however, when it is absent gene 
expression is turned on. Therefore, in the context of this chapter and thesis, the Tet-off system 
allows for the induction of PMCA antisense expression when doxycycline is removed from 
the culture medium. The Tet-off system also allows for gene expression to be switched on 
only when required at the onset of experiments, as constitutive expression of PMCA antisense 
may otherwise be deleterious to the establishment of stable clones [261]. Tetracycline-
regulated expression systems additionally have the benefit of providing genetically identical 
controls in the uninduced state and have been used by other investigators to study the 
phenotypic consequences of target protein inhibition via antisense expression without the 
need of sense controls [255, 256]. Finally, the nucleotide sequence incorporated in the 
antisense orientation into the Tet-off system described in this chapter was based on mRNA 
sequence information that is conserved amongst all PMCA isoforms. The inducible antisense 
transcript thus has the potential to inhibit the expression of all PMCA isoforms. This tactic in 
targeting all PMCA isoforms was adopted to explore if the function of the PMCA extended 
beyond its basic biochemical role as a Ca2+ transporter and thus may potentially have 
responsibilities in important cellular processes that regulate mammary gland physiology and 
pathophysiology. 
 
This chapter comprises of a paper that has been published in the Journal of Biological 
Chemistry and has been included here in slightly amended format [232]. This is followed by 
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unpublished supplementary material that helps validate the model used in the above paper as 
well as support some of its findings.  
 
3.2 Antisense Mediated Inhibition of the Plasma Membrane Calcium-
ATPase Suppresses Proliferation of MCF-7 Cells* 
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Roberts-Thomson‡, Gregory R. Monteith‡¶ 
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DMEM, Dulbecco’s Modified Eagle’s Medium; FBS, fetal bovine serum; DOX, doxycycline; 
MTS, (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium inner salt; FACS, fluorescence activated cell sorting; PBS, phosphate-buffered 
saline; BrdU, 5-bromo-2'-deoxyuridine; FITC, fluorescein isothiocyanate; 7-AAD, 7-amino-
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actinomycin D; [Ca2+]i, free intracellular Ca2+ concentration; HEPES, 4-(2-
hydroxyethyl)piperazine-1-ethanesulfonic acid; PSS, physiological salt solution; BAPTA, 
1,2-Bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid tetrapotassium salt; CPA, 
cyclopiazonic acid; SERCA, sarco(endo)plasmic reticulum Ca2+-ATPase; ATP, adenosine 5'-
triphosphate SD, standard deviation; SEM, standard error of the mean.  
 
3.2.1 Abstract 
Alterations in calcium signaling may contribute to tumorigenesis and the mechanism 
of action of some anti-cancer drugs. The plasma membrane calcium-ATPase (PMCA) is a 
crucial controller of intracellular calcium signaling. Altered PMCA expression occurs in the 
mammary gland during lactation and in breast cancer cell lines. Despite this, the 
consequences of PMCA inhibition in breast cancer cell lines have not been investigated. In 
the report herein we used Tet-off PMCA antisense expressing MCF-7 cells to assess the 
effects of PMCA inhibition in a human breast cancer cell line. At a level of PMCA inhibition, 
which did not completely prevent PMCA-mediated calcium efflux and did not induce cell 
death, a dramatic inhibition of cell proliferation was observed. FACS analysis indicated that 
PMCA antisense involves changes in cell cycle kinetics but not cell cycle arrest. We conclude 
that modulation of the PMCA has important effects in regulating the proliferation of MCF-7 
human breast cancer cells.  
 
3.2.2 Introduction 
Free intracellular calcium (Ca2+)1 acting as a second messenger is crucial for a diverse 
range  of biological functions such as fertilization, neurotransmission, muscle contraction and 
gene transcription [1, 2]. Intracellular Ca2+ signaling is also a key regulator of proliferation 
[262], cell cycle progression [60] and apoptosis [28]. Modulation of capacitative Ca2+ entry, a 
mechanism whereby the influx of extracellular Ca2+ is coupled to the depletion of intracellular 
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Ca2+ stores within the endoplasmic reticulum, is associated with the proliferative phenotype 
[207]. Indeed, blockers of Ca2+ entry may be potential anti-proliferative agents [263, 264]. 
Inhibition of Ca2+/calmodulin dependent serine/threonine protein kinase II also arrests HeLa 
cells in the G2 phase of the cell cycle [265] and apoptotic resistance conferred by 
overexpression of the anti-apoptotic oncoprotein Bcl-2 involves modulation of Ca2+ handling 
by the endoplasmic reticulum [28] and capacitative Ca2+ entry [37, 266]. Although the 
essential role of Ca2+ signaling in maintaining homeostatic functions is well established, less 
is known about the role of aberrant Ca2+ signaling in disease [23, 31].  
 
The plasma membrane Ca2+-ATPase or pump (PMCA) belongs to the family of P-type 
ATPases and is a critical regulator of free intracellular Ca2+ [7]. It actively extrudes Ca2+ 
across the plasma membrane and is important for maintaining basal cytosolic Ca2+ levels and 
lowering free intracellular Ca2+ after the generation of Ca2+ transients and other Ca2+ signaling 
events [2, 97]. The PMCA has important roles in shaping the dynamics of Ca2+ signaling as 
its activation can limit Ca2+ influx during capacitative Ca2+ entry [121]. Moreover, PMCA 
overexpression decreases both the amplitude and duration of cytosolic Ca2+ responses after 
agonist-induced stimulation [120]. 
 
There are four isoforms of the PMCA (PMCA1−4) with additional isoform diversity 
generated from the primary PMCA transcripts by alternative splicing [7, 99]. Upregulation of 
PMCA2 and downregulation of PMCA4 in the rat mammary gland during lactation may 
indicate that PMCA isoforms regulate differentiation and proliferation of the mammary gland 
[17].  
 
There is also an increasing awareness that alterations in Ca2+ signaling regulators are 
associated with tumorigenesis, including that of the mammary gland [267]. Indeed, relative 
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PMCA1 mRNA expression is greater in tumorigenic MCF-7 and MDA-MB-231 breast cancer 
cells, compared to non-tumorigenic MCF-10A cells [15]. PMCA1 and PMCA4 expression is 
also lower in human skin fibroblasts transformed by simian virus 40 [14]. Thus, perturbed 
regulation of PMCA expression or function may be important in diseases such as cancer. 
Therapeutic modulation of PMCA expression and/or activity may have functional 
consequences in suppressing the tumorigenic phenotype. The appropriateness of the PMCA as 
a possible drug target is also demonstrated by the prominence of other clinically used 
inhibitors of P-type ATPases, digoxin and omeprazole, as inhibitors of the Na+/K+-ATPase 
and H+/K+-ATPase, respectively [190, 268]. 
 
Despite the dynamic regulation of PMCA expression in the mammary gland, the 
consequences of PMCA inhibition in breast cancer cell lines has not been addressed. Our aim 
was to investigate whether PMCA inhibition alters Ca2+ homeostasis, cell proliferation and 
cell death in MCF-7 human breast cancer cells. 
  
3.2.3 Materials and Methods 
3.2.3.1 Cell Culture 
MCF-7 Tet-off cells (BD Biosciences Clontech, Palo Alto, CA) were grown in 
DMEM supplemented with 10 % FBS, 4 mM L-glutamine, 100 µg/ml G-418, 100 units/ml 
penicillin G and 100 µg/ml streptomycin with the addition of 110 µg/ml hygromycin B and 
100 ng/ml doxycycline (DOX) as required. All cultures were maintained at 37° C in a 
humidified 5 % CO2/95 % air incubator.  
 
3.2.3.2 Construction of PMCA Antisense cDNA and Cloning 
A 286 base pair cDNA fragment was amplified by RT-PCR from MCF-7 Tet-off cells 
and cloned into the bi-directional pBI-G response plasmid (BD Biosciences Clontech) to 
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generate the PMCA antisense construct. The following primers were used to amplify the 
cDNA fragment: forward primer, 5’-TAGGTCGACGAAATGTCTATGACAGCAT-3’ and 
reverse primer, 5’-TAGGTCGACGGGCCCATTATCTTCTTCATCAT-3’. These primers 
were based on sequence information that is conserved across all human PMCA isoforms. A 
Sal I restriction enzyme site (italics) was introduced into each primer to facilitate cloning and 
an Apa I site (underlined) was incorporated into the reverse primer to assist in directional 
cloning. The PCR product was digested with Sal I and inserted into the Sal I site of the pBI-G 
plasmid in the antisense orientation. Following nucleotide sequencing of the antisense 
construct, the cDNA fragment sequence was compared against GenBank using BLAST 2.2.8. 
 
3.2.3.3 Generation of a Double-stable MCF-7 Tet-off PMCA Antisense-transfected Cell Line 
Parental MCF-7 Tet-off cells already stably transfected with the regulatory 
tetracycline-controlled transactivator were co-transfected using Lipofectamine 2000 
(Invitrogen, Mount Waverley, VIC, Australia) with the prepared pBI-G PMCA antisense 
plasmid and the pTK-Hyg hygromycin B resistance plasmid (BD Biosciences Clontech). 
Hygromycin B-resistant clones were isolated (total of 43) and screened for tetracycline-
regulated β-galactosidase expression. β-galactosidase acted as an indirect reporter for the 
simultaneous expression of PMCA antisense RNA when DOX was removed from the culture 
medium. Screening was performed using the β-galactosidase Enzyme Assay System with 
Reporter Lysis Buffer in accordance with the manufacturer’s instructions (Promega, 
Annandale, NSW, Australia). Eight colonies that showed differing degrees of tetracycline-
regulated β-galactosidase activity (2−10-fold increases upon DOX removal) were further 
screened for effect on PMCA protein with the non-isoform-specific PMCA antibody 5F10. 
From these colonies, three clones were assessed in subsequent proliferation assays and from 
the three, one clone (A7) was selected for more detailed characterization. 
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3.2.3.4 Proliferation Assays 
Cells were plated at 800 cells/well in 96-well plates by initially seeding them in DOX- 
and hygromycin B-free media (100 µl/well). DOX was then added to or omitted from wells at 
the time of plating (day 0). Cells were grown over a 2 week period with the medium renewed 
every 2 to 3 days except on the last day of the experiment. The proliferation of viable cells 
was monitored daily from days 3 to 13 via a colorimetric MTS assay [269], by directly adding 
CellTiter 96 AQueous One Solution Reagent (20 µl; Promega) to each well and incubating 
plates for 2 h at 37° C in a humidified 5 % CO2/95 % air environment. After 2 h, absorbances 
were read at 490 nm with a Bio-Rad Model 550 microplate reader (Hercules, CA).  
 
3.2.3.5 Immunoblotting 
Protein was isolated from cells plated into 10 cm diameter dishes at 1 × 105 cells/dish. 
Cells were seeded in DOX- and hygromycin B-free media and then were adjusted at the time 
of plating to include hygromycin B, either with or without DOX (100 ng/ml). On days 3, 7 
and 13, cells were trypsinized and stored as cell pellets at −80° C until further processing for 
total protein isolates. Total protein was analysed by immunoblotting as described previously 
[270]. For each sample, 40 µg of total protein was loaded onto 7.5 % gels. Antibodies were 
used at the following dilutions and incubated for 1 h at room temperature; 1:2000 for 5F10 
(Affinity BioReagents, Golden, CO), 1:1000 for JA9 (kind gift from Dr John T Penniston, 
Dept Biochemistry and Molecular Biology, Mayo Foundation, Rochester, MN), 1:1000 for 
NR1 (Affinity BioReagents), 1:1000 for NR2 (Affinity BioReagents), 1:1000 for IID8 
(Affinity BioReagents) and 1:10,000 for anti-β-actin (AC-15, Sigma-Aldrich, Sydney, NSW, 
Australia). A goat anti-mouse or goat anti-rabbit IgG horseradish peroxidise-conjugated 
secondary antibody (Bio-Rad, Hercules, CA) was diluted 1:2000 or 1:1000, respectively and 
used as required with incubations for 1 h at room temperature. Proteins were visualized via 
enhanced chemiluminescence (ECL™, Amersham Biosciences, Castle Hill, NSW, Australia). 
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Densitometry measurements of immunoblot bands were analyzed using MetaMorph Version 
4.01 imaging software (Universal Imaging Corporation; Downingtown, PA). For each 
immunoblot, the optical density values for bands representing total PMCA, PMCA4, PMCA1, 
PMCA2 and SERCA2 were normalized to the corresponding value for the β-actin band in 
each lane. 
 
3.2.3.6 Fluorescence Activated Cell Sorting (FACS) Analysis of DNA Content 
Cells were plated at 5 × 105 cells/dish in 10 cm diameter dishes, in DOX- and 
hygromycin B-free media then grown either in the presence or absence of DOX. On days 7 
and 13, cells were harvested from dishes by collecting trypsinized cells together with floating 
cells in the medium. For each condition, a volume of the cell suspension corresponding to 2 × 
106 cells was centrifuged and the resultant cell pellet was resuspended in ice-cold PBS (0.5 
ml). Cells were fixed in ice-cold 70 % ethanol and stained with propidium iodide. FACS 
analysis was performed using a BD FACSCalibur™ flow cytometer (BD Biosciences 
Immunocytometry Systems, San Jose, CA). DNA content histograms and cell cycle phase 
distributions were modelled from at least 10,000 single events by excluding cell aggregates 
based on scatter plots of fluorescence pulse area versus fluorescence pulse width using 
ModFit LT™ Version 2.0 (Mac) software (Verity Software House, Topsham, ME). 
 
3.2.3.7 5-bromo-2'-deoxyuridine (BrdU) Pulse-Chase Analysis of Cell Cycle Progression  
Cells that had been growing in the presence or absence of DOX-containing media for 
six days were plated at 1 x 106 cells/dish in 10 cm diameter dishes. After a further 24 h in the 
appropriate media (± DOX), the cells were pulsed with either PBS or 5-bromo-2'-
deoxyuridine 10 µM (BrdU) for 1 h, followed by one wash with PBS. After washing, the cells 
were then maintained in the appropriate media (± DOX) until being trypsinized, centrifuged at 
300 × g for 5 min and fixed at 0, 3, 6, 12 and 24 h post-BrdU pulse. Collected cells were fixed 
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and stained with the BD Pharmingen FITC BrdU Flow Kit (BD Biosciences Pharmingen, 
North Ryde, NSW, Australia) according to the manufacturer’s instructions. Briefly, 
paraformaldehyde-fixed and saponin-permeabilized cells were incubated for 1 hour at 37° C 
with DNase (300 µg/ml in PBS). BrdU and total DNA were then stained with a FITC-
conjugated anti-BrdU antibody and 7-amino-actinomycin D (7-AAD), respectively. Data were 
acquired using a BD FACSCalibur™ flow cytometer with BD CellQuest™ Version 3.3 
software. For each sample, data were displayed using WinMDI Version 2.8 (Joseph Trotter, 
http://facs.scripps.edu/software.html) by first gating at least 10,000 events to select a 
population of single cells based on density plots of 7-AAD fluorescence pulse area (FL3-A) 
versus 7-AAD fluorescence pulse width (FL3-W). Using this subpopulation of cells, density 
plots of FITC-conjugated anti-BrdU antibody fluorescence pulse height (FL1-H) versus 7-
AAD fluorescence pulse height (FL3-H) were generated. Negative BrdU controls where cells 
were pulsed with PBS were used to set the position of quadrant markers. 
 
3.2.3.8 Assessment of Cell Morphology 
Double-stable MCF-7 Tet-off PMCA antisense-transfected cells were plated onto 25 
mm diameter coverslips placed in a 6-well plate, at 1.8 × 104 cells/well and grown either in 
the presence or absence of DOX. On day 13 of culture, phase contrast images at 200 × 
magnification were taken from five random fields using a Nikon Eclipse TE300 microscope 
(Nikon Instech, Kawasaki, Japan) and MetaFluor Version 4.01 imaging software (Universal 
Imaging Corporation, Downingtown, PA). 
 
3.2.3.9 Assessment of Calcium Efflux 
The efflux of free intracellular Ca2+ was assessed using a fluorescence microplate 
reader to monitor the rate of decline in free intracellular Ca2+ concentration ([Ca2+]i) after the 
generation of ionomycin-induced Ca2+ transients that ranged in magnitude with varying 
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concentrations of the Ca2+ ionophore. Subconfluent double-stable MCF-7 Tet-off PMCA 
antisense cells grown in DOX were subcultured at a split ratio of 1:10 into new T-75 cm2 
flasks containing fresh medium either with or without DOX (100 ng/ml) and grown for 6 
days. After 6 days, cells were plated into polystyrene 96-well plates at 4 × 104 cells/well in 
growth medium (100 µl/well), with or without DOX as previously treated. Cells were allowed 
to adhere for 24 h before loading cells with the non-ratiometric Ca2+ indicator fluo-4 AM (8 
µM; Molecular Probes, Eugene, OR) in loading buffer. Loading buffer (pH 7.3) was 
composed of 5.9 mM KCl, 1.4 mM MgCl2, 10 mM HEPES, 1.2 mM NaH2PO4, 5 mM 
NaHCO3, 140 mM NaCl, 11.5 mM glucose, 1.8 mM CaCl2 and 3 mg/ml bovine serum 
albumin. Cells were loaded at 37° C for 30 min, washed once with loading buffer (no 
indicator) and once with physiological salt solution (PSS). PSS (pH 7.3) contained 5.9 mM 
KCl, 1.4 mM MgCl2, 10 mM HEPES, 1.2 mM NaH2PO4, 5 mM NaHCO3, 140 mM NaCl, 
11.5 mM glucose and 1.8 mM CaCl2. The cells were then incubated for 15 min in PSS at 
room temperature (21 ± 2° C) to minimize indicator leakage and sequestration into 
intracellular organelles. The PSS was removed and cells were washed once with loading 
buffer and then twice with PSS where NaCl was replaced with an equimolar amount of N-
methyl-D-glucamine and CaCl2 was excluded (Na+/Ca2+-free PSS). Cells loaded with fluo-4 
were stimulated with 50 to 420 nM ionomycin in Na+/Ca2+-free PSS containing 100 µM 
BAPTA (Molecular Probes) and 5 µM cyclopiazonic acid (CPA) to obtain various levels of 
peak [Ca2+]i and establish a Ca2+ efflux profile curve. A Ca2+ chelator, BAPTA, was included 
to block Ca2+ influx [271]. The addition of CPA prevented Ca2+ sequestration into the 
endoplasmic reticulum by SERCA and this concentration was selected based on previous 
studies [272] and after CPA dose−response curves were generated in MCF-7 cells (data not 
shown). Na+/Ca2+-free PSS was used throughout the experiment to prevent the Na+/Ca2+ 
exchanger contributing to Ca2+ efflux [122, 271]. Hence the rate of decline in [Ca2+]i was 
predominately a measure of PMCA-mediated free intracellular Ca2+ efflux. Experiments were 
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performed using a NOVOstar fluorescence microplate reader (BMG LabTechnologies, 
Offenburg, Germany). Fluo-4 was excited at 485 nm and fluorescence emission was detected 
at 520 nm. Fluo-4 fluorescence data points were acquired every 1.5 s. All experiments were 
performed at 31 ± 1° C. Relative changes in [Ca2+]i using fluo-4 were determined by 
calculations of ∆F/F, where ∆F/F = (Ft – F0)/F0. In this equation, Ft equals the fluorescence 
reading at each time point (t) and F0 represents initial fluorescence at t = 0 [273]. For each 
well, where peak [Ca2+]i was obtained within 90.5 s following the addition of ionomycin, the 
fluorescence data corresponding to the 60 s after and including the peak ∆F/F was fitted to a 
monoexponential curve as a measure of the rate of PMCA-mediated free intracellular Ca2+ 
efflux [122]. 
 
3.2.3.10 Statistical Analyses 
All data points are presented as means ± SD unless otherwise stated, for the number of 
replicates (n) indicated. Meaningful comparisons between groups were analyzed for statistical 
significance using a two-sided Student’s t-test with significance set at P < 0.05.  
 
3.2.4 Results 
3.2.4.1 PMCA Antisense Induction Suppresses Proliferation of MCF-7 Tet-off Breast Cancer 
Cells 
To generate a cell line where PMCA antisense could be tightly controlled and 
equivalent levels of expression could be obtained, we generated a MCF-7 Tet-off PMCA 
antisense cell line, where the removal of DOX induced PMCA antisense expression (see 
materials and methods). Based upon initial screening for tetracycline-regulated β-
galactosidase expression as a marker for the simultaneous expression of PMCA antisense and 
the sensitivity of PMCA expression to DOX removal, proliferation assays were conducted for 
three MCF-7 Tet-off PMCA antisense-transfected clones. All three clones exhibited inhibition 
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of proliferation upon antisense induction and one clone (A7) was selected for more detailed 
characterization. The effect of antisense expression on proliferation is shown in Fig. 3.1A for 
A7. Controls included identical experiments using parental MCF-7 Tet-off cells (Fig. 3.1B) 
and a MCF-7 Tet-off cell line with regulated expression of both β-galactosidase and a protein 
unrelated to the PMCA (Fig. 3.1C). The induction of PMCA antisense (DOX absence) 
profoundly suppressed the proliferation of MCF-7 (A7) cells over a period of 13 days (Fig. 
3.1A). The removal of DOX did not affect the proliferation of the controls (Fig. 3.1B and 
3.1C). 
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Figure 3.1. Effect of PMCA antisense induction on the proliferation of MCF-7 cells as 
monitored by MTS assays. Cells were cultured in either the presence (+) or absence (−) of 
doxycycline (DOX; 100 ng/ml) for up to 13 days. A) MCF-7 Tet-off PMCA antisense cells 
(clone A7). B) Parental MCF-7 Tet-off cells. C) MCF-7 Tet-off cells with regulated 
expression of an unrelated protein. The data points in Fig. 3.1 represent means of 4 replicate 
wells ± SD and are representative of two independent experiments. 
 
3.2.4.2 Effect of PMCA Antisense Induction on PMCA Protein Expression 
To evaluate whether tetracycline-regulated PMCA antisense inhibits PMCA protein 
expression, we used immunoblotting (Fig. 3.2) to probe for total PMCA protein using the 
non-isoform-specific 5F10 antibody and isoform-specific antibodies to PMCA4, PMCA1 and 
PMCA2 [104]. Immunoblots were repeated twice for two independent sets of protein isolated 
from MCF-7 (A7) cells. A representative immunoblot is shown for total PMCA protein (Fig. 
3.2A). As shown by densitometry measurements, a significant (P = 0.005) decrease in total 
PMCA protein expression was observed on day 13, in cells expressing PMCA antisense 
(DOX absence) compared to no antisense-expressing cells (DOX presence) (Fig. 3.2B). 
Relative PMCA4 levels increased with days in culture implicating a potential role for PMCA4 
in proliferation and this increase was inhibited in cells expressing antisense (Fig. 3.2C−D). By 
day 13 of growth, PMCA4 protein expression was significantly (P = 0.007) lower in PMCA 
antisense-induced MCF-7 (A7) cells, in contrast to the parallel non-induced control (Fig. 
3.2D). We also show for the first time, PMCA1 and PMCA2 protein in MCF-7 cells (Fig. 
3.2E and 3.2G). PMCA1 was only modestly increased in relative expression with days in 
culture, which was not significantly attenuated by PMCA antisense (Fig. 3.2E−F). Consistent 
with its likely role in specific cellular functions, such as lactation [17, 21], PMCA2 levels did 
not alter with days in culture and proliferation (Fig. 3.2G−H).   
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Figure 3.2. Protein expression of total PMCA and specific PMCA isoforms in MCF-7 Tet-off 
PMCA antisense cells (clone A7). Cells were cultured in either the presence (+) or absence 
(−) of doxycycline (DOX; 100 ng/ml) and harvested after 3, 7 and 13 days of growth. A) A 
representative immunoblot probed for total PMCA protein with the 5F10 antibody and B) the 
corresponding densitometry measurements of bands representing total PMCA normalized to 
the β-actin band in each lane. C) A representative immunoblot probed for PMCA4 protein 
with the JA9 antibody and D) the corresponding densitometry measurements of bands 
representing PMCA4 normalized to the β-actin band in each lane. E) A representative 
immunoblot probed for PMCA1 protein with the NR1 antibody and F) the corresponding 
densitometry measurements of bands representing PMCA1 normalized to the β-actin band in 
each lane. G) A representative immunoblot probed for PMCA2 protein with the NR2 antibody 
and H) the corresponding densitometry measurements of bands representing PMCA2 
normalized to the β-actin band in each lane. The bars in Fig. 3.2B, 3.2D, 3.2F and 3.2H 
represent means ± SEM for n = 4 replicates. The asterisk (∗) denotes a statistically significant 
difference (P < 0.05). 
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3.2.4.3 Effect of PMCA Antisense Induction on SERCA2 Protein Expression 
Due to the regulatory link between PMCA and SERCA expression [274], we assessed 
the effects of PMCA antisense-mediated inhibition of MCF-7 cell proliferation on SERCA2 
expression. The modest increase in SERCA2 expression at day 13 was attenuated when MCF-
7 cell proliferation was inhibited via PMCA antisense (Fig. 3.3). 
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Figure 3.3. Expression of sarco(endo)plasmic reticulum calcium-ATPase 2 (SERCA2) 
protein in MCF-7 Tet-off PMCA antisense cells (clone A7). Cells were cultured in either the 
presence (+) or absence (−) of doxycycline (DOX; 100 ng/ml) and harvested after 3, 7 and 13 
days of growth. A) A representative immunoblot probed for SERCA2 protein with the IID8 
antibody and B) the corresponding densitometry measurements of bands representing 
SERCA2 normalized to the β-actin band in each lane. The bars in Fig. 3.3B represent means ± 
SEM for n = 4 replicates. The asterisk (∗) denotes a statistically significant difference (P < 
0.05). 
 
3.2.4.4 PMCA Antisense Induction Alters Cell Cycle Phase Distribution 
We next investigated the effect of PMCA antisense on cell cycle phase distribution by 
performing FACS analysis of DNA content using asynchronous cultures of MCF-7 (A7) cells, 
which were grown in either the presence or absence of DOX for 7 and 13 days. Fig. 3.4 shows 
for each growth condition, percentages of the total number of cells modeled, that were present 
in G0/G1, S or G2/M phases of the cell cycle. There were no significant differences in the 
percentage of cells in G0/G1 phase, between MCF-7 (A7) cells grown in either the presence or 
absence of DOX for both 7 and 13 days (Fig. 3.4A). However, PMCA antisense induction 
significantly (P = 0.005, day 7; P = 0.006, day 13) decreased the percentage of cells present in 
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S phase (Fig. 3.4B). PMCA antisense induction also significantly (P = 0.008, day 7; P = 
0.013, day 13) increased the percentage of cells in G2/M phase (Fig. 3.4C). FACS analysis 
revealed the absence of a noticeable sub-G0/G1 peak, at either day 7 or 13, in a set of 
propidium iodide-stained PMCA antisense-induced MCF-7 (A7) cells (data not shown).  
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Figure 3.4. Effect of PMCA antisense induction on cell cycle phase distribution as 
determined by FACS analysis of MCF-7 Tet-off PMCA antisense cells (clone A7). Cells were 
cultured in either the presence (+) or absence (−) of doxycycline (DOX; 100 ng/ml) and 
harvested after 7 and 13 days of growth. The panels represent results for the percentage of 
total number of cells analyzed that were present in A) G0/G1 phase, B) S phase and C) G2/M 
phase of the cell cycle. The bars in Fig. 3.4 are indicative of means ± SD for three 
independent experiments. The asterisk (∗) denotes a statistically significant difference (P < 
0.05).  
 
To further assess the mechanism by which PMCA antisense induction inhibited the 
proliferation of MCF-7 (A7) cells, we conducted BrdU pulse-chase experiments. Results (Fig. 
3.5) are representative of two independent experiments. PMCA antisense induction (DOX 
absence) in MCF-7 (A7) cells resulted in fewer BrdU-positive cells at 0 h after the BrdU 
pulse (12–12.9 %) compared to the controls (DOX presence; 26–26.8 %). This is consistent 
with the significant reduction of S phase cells as previously shown in Fig. 3.4B. At 6 h post-
pulse cells were progressing into G2/M in both control and antisense-induced groups. At 12 h, 
the emergence of a BrdU-positive peak with a G0/G1 DNA content in both PMCA antisense-
induced (DOX absence) and -non-induced controls (DOX presence) indicated that PMCA 
antisense-induced cells were still actively transiting S and G2/M phases (Fig. 3.5A). Thus 
PMCA antisense expression in MCF-7 (A7) cells did not result in S or G2/M phase arrest. At 
24 h post-pulse, PMCA antisense induction resulted in fewer BrdU-positive cells with a G0/G1 
DNA content (11.3−12.4 %), compared with controls (26.2−27.5 %), indicating a slower 
transition through G2/M phase. No apparent differences in S and G2/M phase progression 
were found for parental MCF-7 Tet-off cells at the 0, 6 and 12 h time points (data not shown) 
or the 24 h time point (Fig. 3.5B).  
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Figure 3.5. Effect of PMCA antisense induction on cell cycle phase progression as 
determined by dual 5-bromo-2'-deoxyuridine (BrdU)- and 7-amino-actinomycin D (7-AAD)-
stained FACS analysis of MCF-7 Tet-off PMCA antisense cells (clone A7). Cells were 
cultured in either the presence (+) or absence (−) of doxycycline (DOX; 100 ng/ml) for 7 
days, pulsed with BrdU 10 µM for 1 h and then harvested 0, 3, 6, 12 and 24 h post-BrdU 
pulse. A) Results are shown for MCF-7 Tet-off PMCA antisense cells (clone A7) at 0, 6, 12 
and 24 h after the BrdU pulse. B) Results are shown for parental MCF-7 Tet-off cells at 24 h 
after the BrdU pulse. The y-axis (anti-BrdU FITC) indicates whether cells are synthesizing 
DNA or have undergone DNA synthesis with the incorporation of BrdU. The x-axis (7-AAD) 
indicates whether cells have a G0/G1 or G2/M DNA content.  
 
3.2.4.5 Induction of PMCA Antisense Inhibits PMCA-mediated Efflux of Free Intracellular 
Calcium 
The effect of PMCA antisense on the primary functional role of PMCA was assessed 
by comparing the rate of PMCA-mediated efflux of free intracellular Ca2+ between MCF-7 
(A7) cells that were cultured either with or without DOX for 7 days (Fig. 3.6). Data were 
obtained by stimulating Ca2+ transients with ionomycin (50-420 nM) and then monitoring 
PMCA-mediated declines in [Ca2+]i between pairs of wells containing either PMCA 
antisense-induced or -non-induced MCF-7 (A7) cells. Ionomycin was selected to reduce the 
activation of other pathways known to alter PMCA activity [248, 272]. Ca2+ transients 
induced by 300 nM ionomycin and subsequent declines in ∆F/F as a measure of relative 
change in [Ca2+]i show that at this level of PMCA antisense induction, cells could still recover 
to basal levels of [Ca2+]i after Ca2+ ionophore-induced increases (Fig. 3.6A). However, cells 
expressing PMCA antisense (DOX absence) had a slower rate of PMCA-mediated free 
intracellular Ca2+ efflux. This is illustrated by comparisons of the rate of PMCA-mediated 
decline in [Ca2+]i between antisense-expressing cells and cells with no antisense induction, at 
similar levels of peak relative [Ca2+]i (Fig. 3.6B). To assess the effects of PMCA inhibition on 
Ca2+ homeostasis changes induced by physiological stimuli, the peak responses to the 
purinergic receptor activator ATP (100 µM) were assessed. PMCA inhibition increased peak 
responses to this stimulus (Fig. 3.6C). 
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Figure 3.6. PMCA-mediated efflux of free intracellular calcium and peak ATP responses as 
determined by relative changes in fluo-4 fluorescence (∆F/F). MCF-7 Tet-off PMCA 
antisense cells (clone A7) were cultured for 7 days, either in the presence (+) or absence (−) 
of doxycycline (DOX; 100 ng/ml), loaded with the intracellular Ca2+ indicator fluo-4 and then 
PMCA-mediated free intracellular Ca2+ efflux and peak ATP responses were assessed. A) 
Example traces of Ca2+ transients induced by 300 nM ionomycin are shown for a pair of wells 
housing cells that were grown either in the presence of DOX (+DOX; no antisense) or 
absence of DOX (−DOX; antisense). The rate of decline in ∆F/F, after reaching peak ∆F/F, is 
a relative measure of PMCA-mediated free intracellular Ca2+ efflux. B) Rates of PMCA-
mediated decline in ∆F/F were plotted against peak ∆F/F values for valid comparisons of 
PMCA-mediated Ca2+ efflux rates in antisense-induced and -non-induced cells. Data points in 
Fig. 3.6B are means ± SEM. Numbers of replicates for each ionomycin concentration used are 
as follows: 6, 50 nM; 14-18, 100 nM; 23-26 175 nM; 34, 300 nM and 35-38, 420 nM. C) Peak 
∆F/F values induced by ATP 100 µM are shown for cells that were grown either in the 
presence of doxycycline (+DOX; no antisense) or absence of doxycycline (−DOX; antisense). 
Bars represent mean ± SEM (n = 6). 
 
3.2.4.6 PMCA Antisense Induction Alters the Morphology of MCF-7 Tet-off Cells  
Phase contrast images of MCF-7 (A7) cells plated at the same cell density and then 
grown for 13 days, either in the presence or absence of DOX, were taken from five random 
fields (Fig. 3.7). PMCA antisense-induced cells (DOX absence) were subconfluent (Fig. 
3.7B), compared with antisense-non-induced controls (DOX presence) (Fig. 3.7A). Moreover, 
a proportion of MCF-7 (A7) cells with PMCA antisense induction exhibited a large, rounded 
and flat cell morphology (Fig. 3.7B), similar to that we have previously observed for the non-
tumorigenic, “normal” breast cell line MCF-10A (data not shown). 
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Figure 3.7. Assessment of cell morphology as seen by phase contrast microscopy after the 
induction of PMCA antisense. MCF-7 Tet-off PMCA antisense cells (clone A7) were plated 
onto coverslips placed in a 6-well plate, at 1.8 × 104 cells/well and then cultured in either the 
presence (+) or absence (−) of doxycycline (DOX; 100 ng/ml). After 13 days of growth, 
images of cells at 200 × magnification were taken from five random fields. A) The panels on 
the left are images of cells grown in the presence of doxycycline (+DOX; no antisense). B) 
The panels on the right are images of cells grown in the absence of doxycycline (−DOX; 
antisense). 
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3.2.5 Discussion 
Intracellular Ca2+ signaling is essential for a diverse array of cellular functions and 
regulates processes that control both life and death. The PMCA is not merely a mechanism for 
the maintenance of a low resting [Ca2+]i. It also plays a role in shaping the complex dynamics 
of Ca2+ signals [123]. The versatility of Ca2+ signaling in terms of spatial and temporal 
regulation is believed to form the basis of how fluctuations in [Ca2+]i are able to encode a 
diverse array of specific messages controlling many cellular functions. For instance, changes 
in the amplitude and duration of Ca2+ signals can mediate the specificity and efficiency in 
activating different transcription factors [57] and the PMCA is likely to play a key role in 
these events. We sought to investigate the effects of inhibiting the PMCA, a critical regulator 
of intracellular Ca2+ signaling [7], in MCF-7 human breast cancer cells using a tetracycline-
regulated antisense approach. PMCA antisense induction, at levels that do not completely 
block recovery of [Ca2+]i after stimulation and do not induce cell death, suppresses cell 
proliferation, affects cell cycle progression and alters cell morphology in MCF-7 cells. 
 
The PMCA appears to plays an important physiological role in the mammary gland. 
PMCA4 protein from the rat mammary gland increases throughout pregnancy up until 
parturition and then sharply declines at the start of lactation [17]. PMCA2 protein expression, 
however, rises during lactation and is particularly enriched in milk fat globule membranes that 
originate from apical membranes of mammary gland secretory cells [17]. Notably, lactating 
PMCA2-null mice exhibit deficiencies in the Ca2+ enrichment of milk [21]. The PMCA is 
thus likely to be an important mediator of mammary gland physiology. 
 
We used a tetracycline-regulated antisense approach to assess the functional 
consequences of PMCA inhibition in the MCF-7 human breast cancer cell line. This approach 
was necessary because of the current lack of a highly specific pharmacological inhibitor of the 
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PMCA. Other commonly used pharmacological agents include orthovanadate ([VO3(OH)]2-), 
which is a general inhibitor of all P-type ATPases [7] and lanthanum (La3+), which has been 
used to inhibit PMCA-mediated Ca2+ efflux [247] but at high concentrations of La3+, there 
may also be inhibition of Ca2+ efflux mediated by the Na+/Ca2+ exchanger [248]. Stable 
antisense approaches have been used previously by others to study the functional role of the 
PMCA. For instance, inhibition of PMCA1 expression in PC6 pheochromocytoma cells via 
stable antisense hinders neuronal differentiation and neurite extension in response to nerve 
growth factor [43]. A tetracycline-regulated approach to antisense expression possesses 
advantages over the use of antisense oligonucleotides or transient siRNA transfection. It 
bypasses the issues surrounding inefficient and variable uptake [275], which may cause either 
partial or complete inhibition of expression in some cells. A transient transfection would 
make it difficult to confirm if decreased proliferation is due to partial target inhibition or 
complete inhibition in some cells. Moreover, the stable expression of antisense under the 
control of a tetracycline-regulated promoter also allows for the long-term inhibition of protein 
expression [259], which is of particular relevance for proteins with relatively long half-lives 
[276]. Indeed, the half-life of the PMCA has been reported to be approximately 12 days [154]. 
Furthermore, the ability to induce antisense expression only during experiments and not 
during colony selection or culture maintenance reduces the likelihood of very long-term 
adaptive changes to signaling pathways.  
 
Our findings show that the induction of PMCA antisense in the MCF-7 breast cancer 
cell line profoundly suppresses cell proliferation (Fig. 3.1A), being neither a non-specific 
effect of DOX removal from the culture medium (Fig. 3.1B) nor a random effect of 
expression from a tetracycline-regulated promoter (Fig. 3.1C). Immunoblot densitometry 
measurements indicated that PMCA antisense induction inhibited total PMCA protein 
expression (Fig. 3.2A and 3.2B). Our studies also demonstrate for the first time PMCA1, 
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PMCA4 and PMCA2 protein expression in MCF-7 cells. This places the well characterized 
MCF-7 cell line as an outstanding tool to explore the role of individual PMCA isoforms in 
specific signaling pathways and functions. The relatively long half-life of the PMCA [154] 
may account for a significant difference in PMCA protein level being evident only after 
extended days of culture and suggests that the inhibition of new PMCA protein synthesis 
regulates the observed effect on cell proliferation. Even when PMCA-mediated free 
intracellular Ca2+ efflux is inhibited to levels that allow recovery of [Ca2+]i (Fig. 3.6A), we 
saw dramatically reduced cell proliferation, identifying the PMCA as a potential drug target in 
breast cancer. Indeed, the non-estrogen-mediated effects of tamoxifen have been liked to 
augmentation of Ca2+ responses [192], an effect which would also arise from inhibition of the 
PMCA. 
 
FACS analysis showed that PMCA antisense induction did not result in apparent 
apoptotic cell death compared to non-induced controls, rather antisense affected the S and 
G2/M phases of the cell cycle. FACS analysis of DNA content alone (Fig. 3.4) did not 
indicate whether this effect was due to a slow down in cell cycle progression or an arrest in a 
particular phase. BrdU pulse-chase studies showed that the duration for which cells resided in 
the G2/M phase was increased by PMCA antisense and that cells were still able to transit S 
and G2/M phases of the cell cycle (Fig. 3.5). Thus the effect of PMCA antisense on the cell 
cycle involves changes in cell cycle kinetics rather than cell cycle arrest. Phase contrast 
images depicting confluence of cell cultures and cell morphology (Fig. 3.7) not only confirm 
that PMCA antisense inhibits cell proliferation but also results in some cells to acquire an 
enlarged, rounded and flattened appearance characteristic of normal breast epithelia [277]. 
The effect of PMCA antisense is likely to act on the G2/M phase to slow down cell cycle 
progression and may even induce senescence in breast epithelial cells.  
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To evaluate whether the induction of PMCA antisense affected PMCA function and 
not only protein expression, we assessed the relative rates of PMCA-mediated intracellular 
Ca2+ efflux in PMCA antisense-expressing and -non-expressing MCF-7 cells (Fig. 3.6B). The 
suppression of cell proliferation by PMCA antisense induction correlated with the inhibition 
of PMCA-mediated intracellular Ca2+ efflux. Although PMCA antisense altered PMCA-
mediated intracellular Ca2+ efflux, this degree of antisense induction did not affect the 
apparent ability of the cell to eventually recover basal intracellular Ca2+ levels after 
ionomycin-induced increases in [Ca2+]i (Fig. 3.6A). This may explain why suppression of cell 
proliferation was observed upon PMCA antisense induction, without the concomitant 
presence of noticeable cell death. Indeed ATP-induced Ca2+ signaling remained during partial 
PMCA inhibition, although as predicted, when Ca2+ efflux is reduced, peak Ca2+ responses 
were augmented (Fig. 3.6C). Collectively, our results suggest that moderate changes in 
PMCA-mediated Ca2+ efflux can lead to profound cellular consequences, despite the absence 
of major deleterious effects on global intracellular Ca2+ homeostasis. It also supports the 
possibility of how alterations in PMCA function may affect the kinetics of Ca2+ signals in 
specifically regulating various cellular processes such as proliferation [262]. The complex 
dynamic aspects of intracellular Ca2+ signaling in regulating transcription factors has been an 
area of active research [1, 2] and represents a link by which PMCA-mediated modulation of 
Ca2+ signaling could control gene transcription and cell phenotype. Indeed, frequency 
modulation of Ca2+ signals can regulate the activity of nuclear factor-κB (NF-κB) [278], a key 
transcription factor that is important in the control of proliferation in lymphocytes and is also 
abnormally expressed in breast cancer [279]. 
 
There is a growing body of evidence suggesting that the PMCA plays important 
physiological roles in the breast. Our data support this notion and although inhibition of 
PMCA-mediated Ca2+ efflux may limit breast cancer cell line proliferation alone, 
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compromised PMCA function may be able to augment cytotoxic Ca2+ responses together with 
other existing anti-tumor agents like tamoxifen [192]. This and the consequences of inhibiting 
specific PMCA isoforms in MCF-7 cells warrant further investigation.  
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3.3 Supplementary Material 
The following pages contain data that were not incorporated into the paper shown 
above but nonetheless still support its findings [232]. Information is also provided about the 
validation of the MCF-7 Tet-off PMCA antisense-transfected cell line model (clone A7) used 
in this study.  
 
3.3.1 Introduction 
The generation of stable cell lines to inhibit the expression of a protein of interest, 
using for example either an antisense or RNAi approach, can be a valuable method of 
examining phenotypic effects that may require long-term modulation of gene expression [254, 
280]. However, this technique is not without its difficulties in that stable transfection of 
plasmid DNA can lead to spurious outcomes as a result of random integration into the 
genome as well as clonal variability in the extent of gene modulation due to both positional 
and copy-number effects of chromosomal integration [281]. As described in section 3.2.3.3 of 
this chapter, multiple hygromycin B-resistant clones were isolated and screened to select 
candidate MCF-7 Tet-off PMCA antisense clones that showed varying degrees of 
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tetracycline-regulated β-galactosidase activity as a reporter for regulated PMCA antisense 
expression. Eight selected clones were then additionally screened for an effect on total PMCA 
protein expression. Three clones that appeared to exhibit a visually identifiable reduction in 
total PMCA protein expression upon PMCA antisense induction were then used in subsequent 
assays to examine a possible phenotypic effect on cell proliferation. Therefore, the following 
supplementary material contains the results of MTS proliferation assays for two additional 
MCF-7 Tet-off PMCA antisense clones.  
 
MTS proliferation assays rely on mitochondrial dehydrogenase activity to reduce a 
tetrazolium salt substrate to a coloured formazan product [269, 282]. Thus, the effect of 
PMCA antisense induction on total cell counts at defined time points, as an alternative 
measure of cell proliferation, are provided for MCF-7 Tet-off PMCA antisense cells (clone 
A7) in the supplementary material. Furthermore, data showing the absence of distinct sub-
G0/G1 peaks in propidium iodide-stained PMCA antisense-induced MCF-7 (A7) cells are 
included.  
 
The use of a conditional gene expression system such as the Tet-off system affords a 
major advantage over a constitutive one in that modulation of gene expression is inducible at 
the discretion of the experimenter. This in turn can allow for the establishment of stable 
clones able to express a desired transcript and the study of its phenotypic effects when 
induced, which subsequently may compromise cell viability or precipitate cell death [261]. 
Tetracycline-regulated gene expression systems have been documented, however, to exhibit a 
high level of basal expression or ‘leakiness’ of the inducible transcript in the uninduced state 
[261, 283]. Therefore, a tetracycline-regulated stable cell line selected for phenotypic 
characterization ideally should display tight control of highly inducible transcript expression. 
The supplementary material hence contains data that support the capacity of the MCF-7 Tet-
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off PMCA antisense cells (clone A7) characterized in the above paper to stringently induce 
PMCA antisense expression at a relatively high level. It also contains details that validate the 
concentration of DOX used to effectively repress PMCA antisense expression in the 
uninduced state.  
 
3.3.2 Materials and Methods 
3.3.2.1 MTS Proliferation Assays 
MTS proliferation assays were conducted in the same manner as previously described 
in section 3.2.3.4.  
 
3.3.2.2 β-Galactosidase Activity Assays 
The β-galactosidase Enzyme Assay System with Reporter Lysis Buffer (Promega) was 
used to evaluate tetracycline-regulated β-galactosidase activity in MCF-7 Tet-off PMCA 
antisense cell lines. At the time point of analysis, cells were washed twice with PBS, lyzed by 
adding a volume of 1 × Reporter Lysis Buffer (50 µl) and then left at room temperature for 15 
min with intermittent mixing. An equal volume of 2 × Assay Buffer containing 200 mM 
sodium phosphate buffer (pH 7.3), 2 mM MgCl2, 100 mM β-mercaptoethanol and 1.33 mg/ml 
o-nitrophenyl-β-D-galactopyranoside was then added to cell lysates. After a 1 h incubation 
period at 37° C, absorbances were read at 415 nm with a Bio-Rad Model 550 microplate 
reader. For the assessment of tetracycline-regulated β-galactosidase activity in clones B4 and 
B8, cells were plated at 800 cells/well in 96-well plates either in the presence or absence of 
DOX (100 ng/ml), cultured for 96 h and then assayed. For the time-course for β-galactosidase 
induction in clone A7, cells were plated at 2.5 × 104 cells/well in 96-well plates with complete 
medium containing DOX (100 ng/ml) and then were grown for 24 h. Cells were washed twice 
with DMEM and then once again with DMEM containing 10 % FBS, before adding back 
complete medium either with or without the addition of DOX. Cells were assayed 0, 3, 6, 12, 
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24, 48, 72 and 96 h after washing. For the DOX−β-galactosidase dose−response relationship 
in clone A7, cells were plated and grown for 24 h in the same manner. The identical washing 
protocol was then used, before adding back complete medium containing 0, 0.01, 0.03, 0.1, 
0.3, 1, 3, 10, 30 and 100 ng/ml DOX. Cells were assayed 72 h later.  
 
3.3.2.3 Manual Cell Counting 
Cells were plated at 5 × 105 cells/dish in 10 cm diameter dishes, grown either in the 
presence or absence of DOX (100 ng/ml), harvested by collecting trypsinized cells together 
with floating cells and then counted using a haemocytometer with an Improved Neubauer 
ruling pattern (Hausser Scientific Company, Horsham, PA). This method did not discriminate 
between alive or dead cells and was therefore reflective of total cell numbers.  
 
3.3.2.4 FACS Analysis of Sub-G0/G1 DNA Content 
MCF-7 Tet-off PMCA antisense cells (clone A7) were cultured, prepared and 
subjected to FACS analysis according to the method previously described in section 3.2.3.6. 
However, DNA content histograms were drawn from at least 10,000 events by first excluding 
cell aggregates based on density plots of propidium iodide fluorescence pulse area versus 
pulse width and then plotting the data for propidium iodide fluorescence pulse area (PI FL2-
Area) using WinMDI Version 2.8 (Joseph Trotter, http://facs.scripps.edu/software.html). 
Markers were arbitrarily placed to estimate the proportion of cells with a sub-G0/G1 DNA 
content. 
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3.3.3 Results and Discussion  
3.3.3.1 PMCA Antisense Induction Suppresses Proliferation of Other MCF-7 Tet-off PMCA 
Antisense Clones 
The effect of PMCA antisense induction on the proliferation of two other MCF-7 Tet-
off PMCA antisense cell lines as assessed by MTS assays is shown in Fig. 3.8. Inhibition of 
cell proliferation upon DOX removal was apparent in both cell lines, clone B4 (Fig. 3.8A) and 
B8 (Fig. 3.8B). Although PMCA antisense induction only modestly reduced the proliferation 
of clones B4 and B8 when compared to that of clone A7, this phenotypic effect was still 
nevertheless significant in these other cell lines at day 13 of the assay. Furthermore, the effect 
of PMCA antisense induction appeared to be slightly greater in clone B8 than B4 (Fig. 3.8). 
The moderate effect of PMCA antisense induction on the proliferation of clones B4 and B8 
and the apparently minor differences in the sensitivities of these cell lines to antisense-
mediated inhibition of proliferation may be due to variations in the absolute capacity of stable 
MCF-7 Tet-off PMCA antisense cell lines to express the antisense transcript. This possibility 
is supported by the results of tetracycline-regulated activity assays for β-galactosidase, which 
acted as an easily detectable marker for the simultaneous expression of PMCA antisense. For 
example, absorbance values representing absolute β-galactosidase inducibility 96 h after DOX 
removal were approximately 0.16 and 0.69 for clones B4 and B8, respectively (Fig. 3.9). On 
the other hand, the comparative value for clone A7 was approximately 1.62 (Fig. 3.12A, 96h). 
Overall, these results support the finding that PMCA antisense-induced inhibition of 
proliferation in stable MCF-7 Tet-off breast cancer cells was not a random effect of clonal 
variation and that the magnitude of this effect may be dependent on the absolute quantity of 
antisense transcript able to be expressed. 
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Figure 3.8. Effect of PMCA antisense induction on the proliferation of other MCF-7 Tet-off 
PMCA antisense cell lines as assessed by MTS assays. Cells were cultured in either the 
presence (+) or absence (−) of doxycycline (DOX; 100 ng/ml) for up to 13 days. A) Clone B4. 
B) Clone B8. The data points in Fig. 3.8 represent means of 8 replicate wells ± SD. The 
asterisk (∗) denotes a statistically significant difference at day 13 (P < 0.05, two-sided 
Student’s t-test).  
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Figure 3.9. Tetracycline-regulated β-galactosidase activity as a marker for PMCA antisense 
expression in MCF-7 Tet-off PMCA antisense clones B4 and B8. Cells were cultured in either 
the presence (+) or absence (−) of doxycycline (DOX; 100 ng/ml) for 96 h and then assayed 
for β-galactosidase activity. The bars in Fig. 3.9 represent means of 8 replicate wells ± SD.  
 
3.3.3.2 PMCA Antisense Induction Suppresses Proliferation of MCF-7 Tet-off Breast Cancer 
Cells as Measured by Total Cell Counts 
MTS proliferation assays are based on the reductive capacity of metabolically active 
cells and are a good indicator of cell viability [269, 282]. However, this assay does not 
provide a true indication of cell numbers. Therefore, the effect of PMCA antisense induction 
on total cell numbers was manually estimated. Fig. 3.10 shows that PMCA antisense 
induction has an inhibitory effect on the proliferation of MCF-7 Tet-off PMCA antisense cells 
(clone A7), as assessed by total cell counts. PMCA antisense induction significantly reduced 
the total number of MCF-7 Tet-off cells by day 13 of culture. This result is in agreement with 
that obtained with the MTS proliferation assay and also confirms that the induction of PMCA 
antisense adversely affects total cell numbers.  
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Figure 3.10. Effect of PMCA antisense induction on total cell counts of MCF-7 Tet-off 
PMCA antisense cells (clone A7). Cells (5×105) were initially seeded, cultured in either the 
presence (+) or absence (−) of doxycycline (DOX; 100 ng/ml), harvested and then manually 
counted on the days indicated. The bars in Fig. 3.10 represent means of 3 replicate samples ± 
SD. The asterisk (∗) signifies a statistically significant difference (P < 0.05, two-sided 
Student’s t-test). 
 
3.3.3.3 FACS Analysis Reveals the Absence of Cell Death in PMCA Antisense-induced MCF-
7 Tet-off Breast Cancer Cells 
To probe for a possible mechanism by which PMCA antisense induction inhibited the 
proliferation of MCF-7 Tet-off PMCA antisense cells (clone A7), FACS analysis of relative 
DNA content was performed. In a set of propidium iodide-stained PMCA antisense-induced 
MCF-7 Tet-off cells at either day 7 or 13, this method showed the absence of a clear sub-
G0/G1 peak, which would otherwise be indicative of apoptotic DNA fragmentation [284] (Fig. 
3.11). Therefore apoptotic cell death is unlikely to contribute substantially to PMCA 
antisense-induced inhibition of MCF-7 Tet-off cell proliferation.  
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Figure 3.11. FACS analysis of sub-G0/G1 DNA content in MCF-7 Tet-off PMCA antisense 
cells (clone A7) as an indicator of apoptotic cell death. Cells were cultured in either the 
presence (+) or absence (−) of doxycycline (DOX; 100 ng/ml) and harvested after 7 and 13 
days of growth. Propidium iodide-stained cells were subjected to FACS analysis of relative 
DNA content. The panels represent DNA content histograms of cells grown for 7 days in A) 
+DOX or B) −DOX medium and 13 days in C) +DOX or D) −DOX medium. Subjectively 
placed markers provide an estimation of the percentage of dead cells with a sub-G0/G1 DNA 
content [285].  
 
3.3.3.4 MCF-7 Tet-off PMCA Antisense Cells (Clone A7) Exhibit Tight Control of Highly 
Inducible β-galactosidase Activity 
β-Galactosidase assays were used to assess the stringency and scope of tetracycline-
regulated PMCA antisense inducibility in MCF-7 Tet-off PMCA antisense cells (clone A7) as 
well as validate the concentration of DOX that was routinely employed to turn off PMCA 
antisense induction (Fig. 3.12). As Fig. 3.12A shows, these cells displayed properties of low 
basal β-galactosidase activity in presence of DOX. The small degree of leakiness in β-
galactosidase activity observed when DOX was left for extended periods, at the 72 and 96 h 
time points, may in part be due to the degradation of DOX in cell culture medium, which 
 104
would be a situation that is analogous to the effects of DOX biological half-life on the kinetics 
of induction in vivo [286] (Fig. 3.12A). Cell culture medium, however, was consistently 
renewed every 2 to 3 days with new medium containing fresh DOX to potentially counteract 
this minor shortcoming. The time-course for β-galactosidase induction also suggests that 
maximum obtainable PMCA antisense induction, at approximately seven-fold greater than in 
the uninduced state, is achieved 72–96 h after DOX removal (Fig. 3.12A). Thus, MCF-7 Tet-
off PMCA antisense cells (clone A7) display properties of tight and highly inducible control 
of PMCA antisense expression as shown by β-galactosidase activity assays. Fig. 3.12B shows 
the DOX−β-galactosidase dose−response relationship for MCF-7 Tet-off PMCA antisense 
cells (clone A7). This relationship was relatively steep, with the induction of β-galactosidase 
activity being activated at DOX concentrations lower than 3 ng/ml and reaching a maximum 
below concentrations of clearly 0.03 ng/ml (Fig. 3.12B). DOX concentrations equal to or 
above 10 ng/ml effectively repressed β-galactosidase induction (Fig. 3.12B). However, to 
ensure robust repression of PMCA antisense expression in the off state, a DOX concentration 
of 100 ng/ml was selected for use in all subsequent experiments. This concentration was 
consistent with that used in other studies [287, 288]. 
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Figure 3.12. Tight control of highly inducible β-galactosidase activity as a marker for PMCA 
antisense expression in MCF-7 Tet-off PMCA antisense cells (clone A7). A) Time-course for 
β-galactosidase induction. Cells were cultured in either the presence (+) or absence (−) of 
doxycycline (DOX; 100 ng/ml) for various lengths of induction and then assayed for β-
galactosidase activity. The bars in Fig. 3.12A represent means of 8 replicate wells ± SD. B) 
DOX−β-galactosidase dose−response relationship. Cells were cultured in the presence of 
various concentrations of DOX, including 0 ng/ml, before assessing β-galactosidase activity 
72 h later. The data points in Fig. 3.12B represent means of 8 replicate wells ± SD. 
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CHAPTER FOUR 
OVERALL DISCUSSION AND CONCLUSIONS 
 
4.1 Foreword 
Ca2+ as an intracellular messenger regulates virtually every conceivable biological 
process that is essential for life [1, 2]. However, excessive or uncontrolled fluctuations in 
[Ca2+]i can also precipitate cell death [28]. This fine balance between life and death is 
dependent on mechanisms that specifically and reversibly modulate [Ca2+]i to propagate Ca2+ 
signals and maintain overall intracellular Ca2+ homeostasis [2, 22]. PMCAs constitute one 
such mechanism, are influential modulators of Ca2+ signaling and are also essential 
determinants for keeping resting [Ca2+]i very low (approximately 100 nM) [3, 6, 7, 120]. The 
existence of multiple PMCA isoforms and splice variants coupled with their distinct patterns 
of tissue or cell type specific expression have particularly intrigued investigators and suggests 
that distinct PMCA isoforms contribute to different physiological roles [98, 99]. Indeed, gene 
knockout studies are gradually revealing that some PMCA isoforms are essential for 
physiological processes that allow for hearing, maintenance of balance and male fertility [9-
11].  
 
PMCAs are also dynamically expressed in the mammary glands of pregnant and 
lactating rats and appear to be crucial mediators of mammary gland physiology [16, 17]. For 
example, the expression of PMCA2 in the mammary gland is likely to be a substantial 
contributor to milk Ca2+ enrichment [21]. Yet little is known about the roles of PMCA 
isoforms in regulating Ca2+ signaling, proliferation, differentiation and apoptosis in the 
mammary gland. This is despite the fact that the mammary gland is a site of tremendous Ca2+ 
flux during lactation [18-20, 89]. It is also well documented that PMCAs are key modulators 
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of proliferation, differentiation and apoptosis in other model systems [43, 44, 64, 65, 143, 
149-151]. These aforementioned processes are fundamental to normal breast development and 
mammary gland physiology but are also abnormally altered in neoplastic disease states such 
as breast cancer [85-87, 152, 153]. Moreover, our early studies in this area have previously 
shown that breast epithelial cell lines express multiple PMCA isoforms and that PMCA1 
expression is greater in tumorigenic MCF-7 and MDA-MB-231 breast cancer cells when 
compared to non-tumorigenic MCF-10A cells [15]. Therefore, the primary tenet of this thesis 
has been that regulation of PMCA isoform expression is disrupted in mammary gland 
pathophysiology, which in humans exists as breast cancer in its commonest form. Inhibition 
of PMCA expression in a cell culture model of breast cancer may have important 
consequences in modulating intracellular Ca2+ homeostasis, cell proliferation, differentiation 
and apoptosis.  
 
To test these hypotheses, this thesis has sought to compare levels of PMCA isoform 
mRNA expression between a panel of tumorigenic and non-tumorigenic breast epithelial cell 
lines. It has also aimed to inhibit PMCA expression in a cell culture model of breast cancer to 
evaluate the consequences of PMCA inhibition on intracellular Ca2+ homeostasis, cell 
proliferation, differentiation and apoptosis. The pursuit of the first aim has found that PMCA2 
is elevated in the majority of tumorigenic breast cancer cell lines tested, particularly in the 
case of ZR-75-1 cells, leading to the possibility that some primary breast cancers may be 
distinguished by the overexpression of PMCA2. This final chapter will therefore explore the 
possible biological significance of PMCA2 overexpression in breast cancer as well as briefly 
discuss regulation of PMCA isoform expression in the mammary gland. In attempting to 
address the second aim, the generation of a stable MCF-7 Tet-off PMCA antisense cell line 
showed that inhibition of PMCA expression dramatically suppressed cell proliferation without 
inducing cell death, whilst only moderately attenuating PMCA-mediated Ca2+ efflux. This 
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effect was not the result of overt cell cycle arrest in a particular phase or cell death but rather 
appears to be due to impediments in cell cycle progression. This final chapter will thus 
evaluate what this means for PMCAs as potential drug targets in breast cancer. It will also 
examine in further detail the possible downstream cellular mechanisms by which PMCA 
antisense acts to inhibit MCF-7 Tet-off cell proliferation and the implications of this 
uncharacterized pathway. The last chapter will then end with a set of conclusions that will 
hopefully encourage further research into the roles and regulation of Ca2+ signaling in the 
mammary gland. 
 
4.2 Implications of PMCA2 Overexpression in Breast Cancer 
The previously known presence of multiple PMCA isoforms, including that of 
PMCA2, in five tumorigenic breast epithelial cell lines was an interesting result in itself [15], 
particularly since PMCA2 is predominately expressed in excitable tissues such as the brain 
and heart [99]. However, this thesis not only demonstrates that PMCA2 is expressed in a 
larger panel of up to nine breast epithelial cell lines but also shows that relative levels of this 
isoform are greater in the majority of tumorigenic breast epithelial cell lines used in this 
study, when compared to non-tumorigenic cells. Most notably, PMCA2 mRNA expression in 
ZR-75-1 breast cancer cells was more than 100-fold greater than in non-tumorigenic 184B5 
cells. Relative expression levels of PMCA2 mRNA even appeared to vary considerably 
between different breast cancer cell lines. This unexpected result is particularly intriguing 
since PMCA2 is also expressed in abundant amounts in the lactating rat mammary gland [16, 
17]. Once reconciled with the knowledge that PMCA2 expression in the mammary glands of 
lactating rats increases almost 100-fold when compared to that of pregnancy rats, this unusual 
result found in ZR-75-1 cells suggests that some primary breast cancers may be characterized 
by the overexpression of Ca2+ transporters that are usually only physiologically upregulated 
during lactation. The findings of differential expression of PMCA2 mRNA between 
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tumorigenic and non-tumorigenic breast epithelial cell lines indicates that it is not only the 
mere presence of PMCA2 that is likely to be important but rather that the relative abundance 
of PMCA2 expression may have greater implications for mammary gland pathophysiology, 
however, this requires further investigation. Overall, it lends support to the first hypothesis of 
this thesis that regulation of PMCA isoform expression is disrupted in breast cancer. 
However, to more robustly assess the plausibility of deregulated PMCA expression in some 
breast cancers, future endeavours could compare PMCA isoform protein levels in a wider 
bank of tumorigenic and non-tumorigenic breast epithelial cell lines. 
 
Although the biological significance of dynamic PMCA2 expression in the normal 
mammary gland has yet to be directly tested, it is clear that PMCA2 upregulation in the 
rodent mammary gland most likely supplements increased demands for milk Ca2+ enrichment 
during lactation [16, 17, 21]. The functional significance of PMCA2 overexpression in breast 
cancer, if at all present is, however, uncertain. The possibility that some breast cancers retain 
or acquire properties of a mammary gland subjected to the demands of lactation may seem 
controversial, especially if the protective effect of mammary gland changes associated with 
lactation against breast cancer in premenopausal women is taken into account [235]. Yet it is 
becoming increasingly apparent that particular mediators of mammary gland development and 
physiology during both pregnancy and lactation may also contribute to the pathophysiology of 
some breast cancers [90, 229, 238, 239]. For example, the inappropriate secretion of PTHrP 
by breast cancer cells, which is a cytokine also secreted during lactation by the normal 
mammary gland to stimulate bone resorption and thus increase Ca2+ in the blood to match the 
demands of milk Ca2+ concentration [184, 230], may play a role in systemic complications of 
breast cancer. Hypercalcemia in breast cancer, in either the presence or absence of osteolytic 
metastases, is a well known complication that causes severe morbidity and mortality [289]. 
Although the exact mechanisms that mediate hypercalcemia in both instances are currently 
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uncertain, the action of PTHrP on skeletal Ca2+ release appears to be a key factor [289]. Some 
metastatic breast cancer cells may only secrete PTHrP once they are exposed to the bone 
microenvironment, whereas others that have not metastasized may inappropriately adopt a 
phenotype normally associated with lactation and detrimentally secrete PTHrP, hence leading 
to hypercalcemia in the absence of lactation [289]. Therefore the possibility that PMCA2 
overexpression, which up till now has only been reported in the lactating rat mammary gland, 
is involved in the pathophysiology of some breast cancers remains.  
 
One area of mammary gland pathophysiology where PMCA2 overexpression may 
play a role is in the development of microcalcifications. These small mineralized deposits of 
Ca2+ are radiologically detectable in about 40 % of breast cancers and are of particular 
diagnostic utility [290]. The presence of mammographic Ca2+ hydroxyapatite crystals, which 
is also normally found in bone, is more likely to be associated with malignant tumors [290]. 
Functionally, Ca2+ hydroxyapatite crystals stimulate DNA synthesis and proliferation in 
MCF-7 breast cancer cells, as well as increase the expression of certain matrix 
metalloproteinases [291]. These effects appear to be mediated by direct cell−crystal contacts 
rather than the dissolution of Ca2+ hydroxyapatite in culture medium [292]. However, little is 
known about the mechanisms by which mammary gland microcalcifications are formed.  
 
Given that PMCA2 is abundantly upregulated in the mammary glands of lactating rats 
and PMCA2-null mice exhibit inadequacies in milk Ca2+ concentration [16, 17, 21], it is 
speculated that this PMCA isoform participates abnormally in breast cancer to transport Ca2+ 
into intraluminal spaces of the mammary gland, leading to the pathophysiological formation 
of microcalcifications in the absence of lactation. If this was the case, the consequences of 
PMCA2 overexpression in breast cancer may indirectly affect cell proliferation. Therefore, 
future studies should not only address this hypothesis but also investigate the effects of 
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PMCA2 overexpression and/or knockdown on breast cancer cell differentiation, apoptosis and 
phenotypic characteristics of malignancy. Such studies may require three-dimensional cell 
culture systems that allow for Ca2+ concentration within mammospheres since 
microcalcifications may not crystallize using traditional techniques [90, 293]. The conditional 
mutation or deletion of PMCA2 in the mouse mammary gland would also allow investigators 
to directly assess the role of PMCA2 in mammary gland development, post-lactational 
involution and tumorigenesis [294, 295]. This method represents an ideal opportunity to 
evaluate PMCA2 as a potential drug target in breast cancer and is envisaged to have a clear 
advantage over a genome-wide approach since PMCA2-null mice are deaf and thus display 
consequences in other physiological systems [9].  
 
The finding that PMCA2 was abundantly overexpressed in ZR-75-1 cells should not 
overshadow the likelihood that other PMCA isoforms or P-type Ca2+-ATPases may also be 
biologically significant in mammary gland pathophysiology. Furthermore, the possibility that 
PMCA2 overexpression in some breast cancers is a collateral consequence of mammary gland 
tumorigenesis also remains untested. This does not, however, rule out the potential that 
PMCA2 is of clinical value as a diagnostic or prognostic marker in breast cancer. Therefore, 
future studies should also examine the expression of PMCA isoforms in primary human 
breast cancer samples and analyze if associations between PMCA expression and patient 
survival or the expression of other established markers of malignancy exist [225].  
 
These considerations also question the potential mechanisms by which PMCA2 
expression and that of other PMCAs are regulated in the breast. Mammary gland 
development, physiology and gene expression are regulated by numerous hormones such as 
estrogen, progesterone, prolactin and PTHrP [88, 90, 243]. The possibility that PMCA 
isoform expression in the mammary gland is subjected to similar modes of hormonal 
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regulation should also be considered. Alternatively, a more thorough tactic could be applied 
by analyzing PMCA isoform promoter regions and incorporating gene reporter or 
electrophoretic mobility shift assays to delineate the mechanisms of PMCA isoform 
transcriptional regulation in the mammary gland [146, 168]. Studies may also explore the 
control of PMCA isoform expression at both the level of translation and protein degradation. 
Regulation of PMCA isoform gene expression therefore remains a relatively unexplored area 
of research and such systematic strategies will not only hopefully provide clues towards 
unravelling the biological significance of PMCA isoform expression in mammary gland 
pathophysiology but also may elucidate other pathways that could be targeted in breast 
cancer.  
 
4.3 PMCA-mediated Inhibition of Proliferation in MCF-7 Cells: 
Considerations for Breast Cancer 
 Prior to the reports by Reinhardt and colleagues providing evidence towards the 
importance of mammary gland PMCA2 expression as a major means of milk Ca2+ 
concentration [16, 17, 21], virtually nothing was known about the physiological and 
pathophysiological significance of PMCAs in the mammary gland. This thesis, however, 
presented data for the first time suggesting that PMCAs may also be influential mediators of 
mammary gland epithelial cell proliferation. Specifically, it reveals that the induction of 
PMCA antisense in a stable MCF-7 Tet-off breast cancer cell line dramatically suppresses cell 
proliferation. Immunoblots demonstrated that the induction of PMCA antisense significantly 
inhibited the expression of total PMCA and PMCA4 protein after 13 days of culture.  
 
SERCA2 protein expression was also significantly inhibited after 13 days of PMCA 
antisense induction, however, since the expression of both PMCA and SERCA has been 
reported to be co-regulated and that this regulatory link is likely to be mediated by ER Ca2+ 
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content [274], this was not an unexpected result. Indeed, peak ATP-stimulated intracellular 
Ca2+ responses were augmented in PMCA antisense-induced cells, indicating that ER Ca2+ 
stores were altered in these cells [206, 209]. Comparisons of the time-course of protein 
expression between PMCA4 and SERCA2 also suggested that the effect of PMCA antisense 
induction on PMCA4 expression may precede the effect on SERCA2. Although the effect was 
not significant, the expression of PMCA4 protein was modestly inhibited in PMCA antisense-
induced cells by day 7 of culture. A similar trend was not apparent for SERCA2. Therefore, 
PMCA antisense-induced suppression of MCF-7 Tet-off breast cancer cell proliferation is 
most likely to be mediated by PMCA4. PMCA antisense expression also reduced the rate of 
PMCA-mediated free intracellular Ca2+ efflux, providing further support that the observed 
effect on cell proliferation was due to the inhibition of PMCA expression. It did not, however, 
alter the cell’s ability to restore resting intracellular Ca2+ concentration, which suggests that 
partial inhibition of PMCA expression in MCF-7 Tet-off breast cancer cells did not adversely 
affect global intracellular Ca2+ homeostasis. Overall, the data displayed in this thesis not only 
indicated that PMCA antisense-induced inhibition of MCF-7 Tet-off breast cancer cell 
proliferation is a PMCA-mediated effect, most probably acting via PMCA4 but also a Ca2+ 
signaling-mediated effect.  
 
FACS analysis of MCF-7 Tet-off PMCA antisense cells (clone A7), grown in either 
the presence or absence of DOX, was performed to explore the possible mechanism of action 
responsible for PMCA antisense-mediated inhibition of cell proliferation. The results 
comparing the effect of PMCA antisense induction on the proportion of cells in G0/G1, S and 
G2/M phases of the cell cycle suggest that PMCA antisense expression altered cell cycle 
distribution, possibly by hindering G1 progression into S phase and also impeding G2/M 
progression back into G1 phase. This possible scenario is described in further detail both in 
this paragraph and in the one below. Rather than arresting cells in a particular phase of the 
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cell cycle, in a manner similar to the classical G2/M phase arrest produced by paclitaxel or 
nocodazole treatment [296, 297], induction of PMCA antisense may prolong cell cycle 
progression at multiple phases. The reduced rate of entry from G1 into S phase may balance a 
similar reduction in the rate of exit from G2/M back into G1 phase and therefore did not affect 
the percentage of cells present in G0/G1 phase for an asynchronous population. Indeed, the 
experimental anti-proliferative Cdc25 phosphatase inhibitor (NSC 663284) also acts on 
multiple phases of the cell cycle by arresting cell cycle progression at both G1 and G2/M 
phases [298].  
 
It was clear from routine FACS analysis of relative DNA content that PMCA 
antisense induction did not result in a sub-G0/G1 peak, thus indicating that apoptotic cell death 
is unlikely to represent a plausible mechanism underlying the observed effect on cell 
proliferation. Nevertheless, FACS analysis of relative DNA content by itself did not 
distinguish whether the observed effect on MCF-7 Tet-off cell proliferation was either due to 
delays in cell cycle progression or the result of actual cell cycle arrest. To address this 
concern, FACS analysis of BrdU-labelled and 7-AAD-stained MCF-7 Tet-off PMCA 
antisense cells (clone A7) revealed that although these cells were still able to progress through 
S and G2/M phases upon PMCA antisense induction, the duration of G2/M phase was longer. 
The use of this technique also suggested that PMCA antisense induction did not affect the 
length of S phase, as the majority of BrdU-labelled cells in both control and antisense-induced 
groups had progressed into G2/M phase by 6 h. Future studies employing similar methods 
should allow for the direct assessment of G1 phase progression upon PMCA antisense 
expression. For instance, cells could be synchronized in G0 phase prior to growth stimulation 
in the presence of BrdU, coupled with FACS analysis at frequent intervals, to detect the onset 
of S phase and thus provide an estimation of the duration of G1 phase. Additionally, future 
studies addressing the mechanism of PMCA-mediated inhibition of MCF-7 Tet-off cell 
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proliferation could use microarray analysis of transcript expression to identify candidate genes 
that may be involved in this process. Together, these results imply that PMCA antisense-
induced inhibition of proliferation in MCF-7 Tet-off cells is mediated by prolongation in cell 
cycle phase duration and thus alterations in cell cycle kinetics, rather than overt cell cycle 
arrest.  
 
A concept that up till now has only briefly been mentioned but may represent a 
speculative yet alternative means by which PMCA antisense induction inhibits MCF-7 Tet-off 
breast cancer cell proliferation is cellular senescence [299, 300]. Although the biological 
significance of senescence in normal physiological systems is uncertain, it may play a dual 
role depending on cell type, in both mammary gland tumor suppression and progression [299, 
300]. Senescence is a process whereby cells permanently exit the cell cycle with a G1 DNA 
content, are unresponsive to mitogenic stimuli yet remain metabolically active and adopt 
profound morphological changes [299, 301]. During routine experiments using PMCA 
antisense-induced MCF-7 Tet-off cultures, some cells were observed that had acquired 
morphological features indicating a senescent phenotype. This was subsequently confirmed 
subjectively by comparing the morphology between control and PMCA antisense-induced 
MCF-7 Tet-off cells, using random images taken using a phase contrast microscope. These 
images showed that some PMCA antisense-induced cells were of large, rounded and flattened 
appearance, with pronounced cytoplasmic volume, thus suggesting that PMCA-mediated 
inhibition of MCF-7 Tet-off cell proliferation may partly involve a senescence-like 
mechanism [299]. Indeed, the inhibitory effects of insulin-like growth factor binding protein-
related protein 1 on MCF-7 cell proliferation, has similarly been reported to involve the 
induction of senescence [302].  
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Future studies should therefore determine whether reductions in the percentage of S 
phase cells observed in this thesis upon PMCA antisense induction, were due to either 
prolonged G1 phase duration or the induction of cellular senescence in a proportion of cells 
and may require an advanced FACS approach to identify cycling versus non-cycling cells 
[302]. Further evidence that may suggest the involvement of senescence as a possible means 
for PMCA antisense-mediated inhibition of MCF-7 Tet-off cell proliferation could be 
obtained by assessing known markers of senescence such as senescence marker protein 30, 
which interestingly has also been reported to modulate PMCA activity [303]. Proliferation 
assay results from other MCF-7 Tet-off PMCA antisense clones indicating differences in the 
degree of PMCA antisense-induced inhibition of cell proliferation suggests that heterogeneity 
exists between cell lines. Indeed, there appeared to be a correlation between the level of 
PMCA antisense induction and the degree of inhibition of cell proliferation. It is also 
uncertain as to which PMCA isoform or isoforms mediate PMCA antisense-induced 
inhibition of proliferation in MCF-7 Tet-off cells. On-going research will hopefully take 
advantage of RNAi [251, 304] to not only compare the phenotypic effects of partial versus 
complete PMCA inhibition but to also explore which PMCA isoforms are relevant to specific 
cellular processes of mammary gland physiology and pathophysiology.  
 
Finally, this thesis has provided intriguing data suggesting that PMCA antisense-
mediated suppression of MCF-7 Tet-off breast cancer cell proliferation is possibly due to 
inhibition of the PMCA4 isoform and also likely to act via a Ca2+ signaling pathway. 
Consequently, PMCAs in the mammary gland are potentially important drug targets for the 
treatment of breast cancer. Yet, it is unknown whether PMCA-mediated inhibition of cell 
proliferation shown for MCF-7 Tet-off PMCA antisense clones is either a universal biological 
phenomenon of all eukaryotic cells or is specific for tumorigenic mammary gland epithelial 
cells. Thus, future endeavours may need to address issues surrounding the specificity and 
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sensitivity of PMCA-mediated modulation of cell proliferation as systemic inhibition of 
PMCA expression could lead to toxicity. Even if the observed negative effect on MCF-7 Tet-
off cell proliferation upon PMCA antisense induction were to apply to other eukaryotic cells, 
PMCAs and PMCA4 in particular may still be valid drug targets for breast cancer. If breast 
cancer cells were to express lower amounts of PMCA4 compared to surrounding non-
tumorigenic cells of the breast and other tissues, these tumorigenic cells may be inherently 
more sensitive to PMCA-mediated inhibition of cell proliferation at a given level of PMCA4 
inhibition. Indeed, relative PMCA4 levels were moderately lower in tumorigenic breast 
epithelial cell lines when compared to a non-tumorigenic control. Breast cancer cells may 
therefore be more susceptible to PMCA-mediated inhibition of cell proliferation than 
surrounding normal tissue but this hypothesis and the possibility that this effect is sensitive to 
PMCA expression levels needs to be tested. It is also anticipated that although PMCA-
mediated inhibition of breast cancer cell proliferation may reduce tumor burden alone, this 
therapeutic approach would be unlikely to eradicate tumors due to the absence of apoptotic 
cell death. PMCA inhibitors as treatments for breast cancer thus may need to be used in 
conjunction with existing anti-neoplastic agents and may even augment the efficacy of drugs 
like tamoxifen that have been reported to induce cell death via cytotoxic Ca2+ elevations 
[192]. This scenario, the down-stream mechanisms of PMCA-mediated inhibition of MCF-7 
Tet-off cell proliferation and the possibility that PMCAs modulate other important phenotypic 
characteristics of malignant cells require further investigation. Many questions therefore 
remain in this emerging field but this thesis along with other publications that have already 
been mentioned have undoubtedly provided important clues and will hopefully encourage 
future research towards elucidating the biological roles and regulation of PMCAs and Ca2+ 
signaling in the mammary gland.  
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4.4 Conclusions 
• PMCA2 expression is generally upregulated in tumorigenic breast epithelial cell lines 
compared to non-tumorigenic breast epithelial cell lines, particularly ZR-75-1 breast 
cancer cells, which abundantly overexpress PMCA2 
• Some breast cancers may be characterized by the overexpression of PMCA2, an 
isoform that up till now has only been shown to be upregulated in the mammary 
glands of lactating rats 
• PMCA4 is also dynamically expressed in breast epithelial cell lines 
• PMCA isoform expression appears to be deregulated in some breast cancer cell lines 
but the biological significance of this is uncertain 
• Induction of PMCA antisense in MCF-7 Tet-off breast cancer cells profoundly 
suppresses cell proliferation and modestly reduces PMCA-mediated intracellular Ca2+ 
efflux at levels of antisense that do not totally abolish the cell’s ability to maintain 
intracellular Ca2+ homeostasis 
• PMCA antisense induction inhibits both total PMCA and PMCA4 protein and PMCA 
antisense-mediated inhibition of MCF-7 Tet-off cell proliferation is likely to be 
mediated by PMCA4 
• PMCA-mediated inhibition of MCF-7 Tet-off cell proliferation did not result from 
apoptotic cell death 
• Rather than involving overt cell cycle arrest, the mechanism of PMCA-mediated 
inhibition of MCF-7 Tet-off cell proliferation incorporated extended G2/M phase 
progression, thus changing cell cycle kinetics 
• PMCAs represent potential drug targets or biological markers in breast cancer 
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